| Customer Name | ####### | Customer Institutaion | ####### | Customer Email | ####### | Project ID | ####### |
|---|---|
| Salesperson | Kyle Navel | knavel@lcsciences.com |
Your reliable partner in genomics, transcriptomics and proteomics
Circular RNAs (circRNAs) are produced from precursor mRNA (pre-mRNA) back-splicing of thousands of genes in eukaryotes. Although circRNAs are generally expressed at low levels, recent findings have shed new light on their cell type-specific and tissue-specific expression and on the regulation of their biogenesis. Furthermore, the data indicate that circRNAs shape gene expression by titrating microRNAs, regulating transcription and interfering with splicing, thus effectively expanding the diversity and complexity of eukaryotic transcriptomes.
In addition to the circular RNAs that are formed from thousands of loci in eukaryotes by exon back-splicing circularization, different types of circular RNAs exist, which are produced by distinct mechanisms. First, circular viral RNA genomes are ligated by host cellular enzymes to form 3ʹ,5ʹ-phosphodiester bonds or 2ʹ,5ʹ-phosphodiester bonds. Second, circular RNA intermediates can be generated during rRNA processing and permuted tRNA biogenesis in Archaea and algae. Third, a number of housekeeping non-coding RNAs, including small nucleolar RNAs and the ribozyme RNase P, were also identified in circular forms in Archaea. Finally, various circular RNAs that are produced from spliced introns and exons have been reported. For example, excised, self-spliced group I and group II introns are ligated to form circular RNAs with either 3ʹ,5ʹ-phosphodiester bonds or 2ʹ,5ʹ-phosphodiester bonds. Excised tRNA introns are removed by tRNA splicing enzymes and then undergo 3ʹ,5ʹ-phosphodiester ligation in Archaea and Metazoa. Circular RNAs derived from lariat introns have been reported in human cells and in Xenopus tropicalis.
Fig.1 Circular RNA (circRNA) biogenesis and its regulation. Chen,LL. (2016) Nature Reviews Molecular Cell Biology 17[4]:205.
As shown in Fig.1, a. CircRNA is produced by back-splicing circularization, which is catalysed by the spliceosomal machinery. Although it remains unknown exactly how the spliceosome is involved in back-splicing (dashed box), it is proposed that following the sequential assembly of spliceosomal small nuclear ribonucleoproteins (snRNPs) on the precursor mRNA (pre-mRNA), a downstream 5′ donor site of an exon (magenta bars) is joined to an upstream 3′ acceptor site to produce a circRNA. b. Orientation-opposite complementary sequences (red arrows) in introns flanking circularized exons promote circRNA biogenesis by pairing to form RNA duplexes that juxtapose the splice sites. However, alternative splicing may occur and lead to the formation of circRNA with a retained intron (black line). c. Competition for RNA pairing across introns can lead to the formation of different circRNAs from a single gene. d. Muscleblind (Mbl) protein enhances circRNA production from its own gene by binding to introns bracketing the circularized exon15. White diamonds denote Mbl-binding sites. e. A proposed model for quaking (QKI) involvement in circRNA biogenesis during the epithelial–mesenchymal transition (EMT)18. QKI is upregulated during EMT. Low QKI expression in epithelial cells promotes exon inclusion in the linear mRNA, whereas high QKI expression in mesenchymal cells facilitates circRNA formation by juxtaposing the circularized exons. White ovals denote QKI binding sites in QKI-regulated pre-mRNAs. f. A-to-I RNA editing by adenosine deaminase 1 acting on RNA (ADAR1) can suppresses circRNA formation by disrupting RNA pairing between flanking introns.ss, splice site.
Total RNA was extracted using Trizol reagent (Invitrogen, CA, USA) following the manufacturer's procedure. The total RNA quality and quantity were analysis of Bioanalyzer 2100 and RNA 6000 Nano LabChip Kit (Agilent, CA, USA) with RIN number >7.0. Approximately 10 ug of total RNA was used to remove ribosomal RNA according to the manuscript of the Epicentre Ribo-Zero Gold Kit (Illumina, San Diego, USA). Following purification, the ribo-minus RNA fractions is fragmented into small pieces using divalent cations under elevated temperature. Then the cleaved RNA fragments were reverse-transcribed to create the final cDNA library in accordance with a strand-specific library preparation by dUTP method, the average insert size for the paired-end libraries was 300±50 bp. And then we performed the pair-end 2×150bp sequencing on an illumina Hiseq 4000 platform at LC Sciences following the vendor's recommended protocol.
Firstly, Cutadapt[1] and perl scripts in house were used to remove the reads that contained adaptor contamination, low quality bases and undetermined bases. Then sequence quality was verified using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). We used Bowtie2[2] and Tophat2[3] to map reads to the genome of species. Remaining reads (unmapped reads) were still mapped to genome using tophat-fusion[4]. CIRCExplorer[5-6] was used to de novo assemble the mapped reads to circular RNAs at first; Then, back splicing reads were identified in unmapped reads by tophat-fusion and CIRCExplorer. All samples were generated unique circular RNAs. Circular RNA expressions from different samples or groups were caculated by scripts in house. Only the comparisons with p value<0.05 were regarded as showing differential expression by R package edgeR[7].
Bioinformatics pipeline for circRNA (RiboZero)
Reference:
1. Martin M (2011) Cutadapt removes adapter sequences from high-throughput sequencing reads. Embnet Journal 17.
2. Langmead B, Salzberg SL (2012) Fast gapped-read alignment with Bowtie 2. Nature Methods 9: 357-359.
3. Kim D, et al. (2013) TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biology 14: R36.
4. Kim, D., & Salzberg, S. L. (2011). Tophat-fusion: an algorithm for discovery of novel fusion transcripts.Genome Biology , 12(8), R72
5. Zhang, X, et all. (2016). Diverse alternative back-splicing and alternative splicing landscape of circular RNAs. Genome Research, 26(9), 1277-1287.
6. Zhang, X, et al. (2014). Complementary sequence-mediated exon circularization. Cell, 159(1), 134.
7. Robinson, M. D., et al. (2010). Edger: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics, 26(1): 139-40.
Species name: Human
Latin name: Homo sapiens
Specimens: tissue/whole blood
| Sample | COND1 |
| EM01_M | M |
| EM02_M | M |
| EM03_M | M |
| KTY01_K | K |
| KTY02_K | K |
| KTY03_K | K |
| Dababase | Web links | Version/date |
|---|---|---|
| Genome | ftp://ftp.ensembl.org/pub/release-90/fasta/homo_sapiens/dna/ | GRCh38 | Gene Orthology (GO) | http://www.geneontology.org/ | 2016.12 | KEGG | http://www.genome.jp/kegg/pathway.html | 2017.06 |
| Analysis item | Software | Version/date | Quality control | FastQC | 0.10.1 | Adapter remove | Cutadapt | 1.10 | Genome mapping | Tophat | 2.0.4 | Back splicing junction reads filter | Tophat-fusion | 2.1 | CircRNA identification | CIRCExplorer | 1.3 | Differential expression analysis | R package: edgeR | NA | Interaction with miRNA | miRanda & Targetscan for animals | NA | Interaction with miRNA | Targetmimics for plants | NA |
|---|---|---|
Statistics of reads from 6 libraries was shown below. Results of FastQC, PCA analysis and sample correlation were deposited in summary/4_1_Quality_Control.
| Sample | Raw Data | Valid Data | Valid Ratio(reads) | Q20% | Q30% | GC content% | ||
| Read | Base | Read | Base | |||||
| EM01_M | 91097877 | 13.66G | 88481920 | 13.27G | 97.13 | 99.56 | 93.67 | 51 |
| EM02_M | 88733750.50 | 13.31G | 68940088 | 10.34G | 77.69 | 99.57 | 93.75 | 51 |
| EM03_M | 90038586 | 13.51G | 69954810 | 10.49G | 77.69 | 99.56 | 93.75 | 51 |
| KTY01_K | 87751966.50 | 13.16G | 85881284 | 12.88G | 97.87 | 99.59 | 93.78 | 50 |
| KTY02_K | 85468310 | 12.82G | 83676668 | 12.55G | 97.90 | 99.63 | 94.55 | 50 |
| KTY03_K | 93711271.50 | 14.06G | 73363120 | 11.00G | 78.29 | 99.58 | 93.87 | 50 |
document location: summary/1_rawdata/ReadsQC.xlsx
First, we utlized Tophat to align all reads on reference genome. Those unmapped reads including back splicing junctions were filtered by Tophat-fusion. Finally, circRNAs were identified by CIRCExplorer.
Statistics of tophat mapping:
| Sample | EM01_M | EM02_M | EM03_M | KTY01_K | KTY02_K | KTY03_K |
| Valid reads | 68984860 | 53747668 | 54537348 | 67917550 | 67275414 | 57987788 |
| Mapped reads | 61403066(89.01%) | 47921784(89.16%) | 48627522(89.16%) | 60691201(89.36%) | 60947071(90.59%) | 52278895(90.16%) |
| Unique Mapped reads | 59284876(85.94%) | 46290322(86.13%) | 46971952(86.13%) | 59015058(86.89%) | 59310831(88.16%) | 50842143(87.68%) |
| Multi Mapped reads | 2118190(3.07%) | 1631462(3.04%) | 1655570(3.04%) | 1676143(2.47%) | 1636240(2.43%) | 1436752(2.48%) |
| PE Mapped reads | 28591268(41.45%) | 22337066(41.56%) | 22667090(41.56%) | 28186846(41.50%) | 28648791(42.58%) | 24453727(42.17%) |
| Mapped left reads | 31853168(46.17%) | 24837216(46.21%) | 25201550(46.21%) | 31625635(46.56%) | 31402890(46.68%) | 27069515(46.68%) |
| Mapped right reads | 29549898(42.84%) | 23084568(42.95%) | 23425972(42.95%) | 29065566(42.80%) | 29544181(43.92%) | 25209380(43.47%) |
| Reads map to sense strand | 29588508(42.89%) | 23104056(42.99%) | 23444442(42.99%) | 29497002(43.43%) | 29647889(44.07%) | 25413011(43.82%) |
| Reads map to antisense strand | 29696368(43.05%) | 23186266(43.14%) | 23527510(43.14%) | 29518056(43.46%) | 29662942(44.09%) | 25429132(43.85%) |
| Non-splice reads | 37477965(54.33%) | 29256773(54.43%) | 29686513(54.43%) | 38092998(56.09%) | 37119682(55.18%) | 32811360(56.58%) |
| Splice reads | 21806911(31.61%) | 17033549(31.69%) | 17285439(31.69%) | 20922060(30.81%) | 22191149(32.99%) | 18030783(31.09%) |
| Unmapped reads | 7581794(10.99%) | 5825884(10.84%) | 5909826(10.84%) | 7226349(10.64%) | 6328343(9.41%) | 5708893(9.84%) |
| Back-spliced junctions reads | 363193(0.53%) | 277645(0.52%) | 282266(0.52%) | 267292(0.39%) | 289332(0.43%) | 229252(0.40%) |
Statistics of tophat-fusion mapping:
| Sample | EM01_M | EM02_M | EM03_M | KTY01_K | KTY02_K | KTY03_K |
| Candidate back-spliced junction reads | 363193(0.53%) | 277645(0.52%) | 282266(0.52%) | 267292(0.39%) | 289332(0.43%) | 229252(0.40%) |
| Confident post reads | 14245(0.02%) | 10874(0.02%) | 11022(0.02%) | 17840(0.03%) | 17932(0.03%) | 15205(0.03%) |
| CircRNA number | 5161 | 4257 | 4302 | 6521 | 6559 | 5869 |
| CircRNA-hosting gene num | 2902 | 2571 | 2585 | 3244 | 3274 | 3034 |
document location:
summary/2_reference_mapping/2_mapped_stat.xlsx
summary/2_reference_mapping/3_tophat_fusion_mapped_stat.xlsx
Statistics of mapped region:
Statistics of unmapped region (tophat-fusion):
document location:
summary/2_reference_mapping/4_mapped_region_stat.pdf
summary/2_reference_mapping/5_tophat_fusion_mapped_region_stat.pdf
document location: summary/2_reference_mapping/4_DensityDistribution/*_chromosome.jpeg
Exonic circRNAs were defined as "circRNA". Intronic circRNAs were defined as "ciRNA". Intergenic circRNAs were defined as "intergenic".
document location: summary/3_1_circRNA_candidate_prediction/2_circRNA_circType.jpg
| Sample | Exp gene | Min. | 1st Qu. | Median | Mean | 3rd Qu. | Max. | Sd. | Sum. |
| EM01_M | 10904 | 0.02 | 3.34 | 7.05 | 32.49 | 15.34 | 22244.51 | 348.26 | 354245.28 |
| EM02_M | 10883 | 0.02 | 3.33 | 7.06 | 32.56 | 15.34 | 22269.28 | 348.72 | 354307.73 |
| EM03_M | 10883 | 0.02 | 3.32 | 7.07 | 32.56 | 15.36 | 22273.99 | 348.76 | 354336.01 |
| KTY01_K | 10891 | 0.01 | 4.69 | 9.84 | 27.37 | 20.05 | 6462.67 | 152.43 | 298060.74 |
| KTY02_K | 10906 | 0.01 | 4.59 | 9.47 | 28.63 | 19.37 | 9601.09 | 185.48 | 312283.27 |
| KTY03_K | 10885 | 0.01 | 4.69 | 9.85 | 27.39 | 20.16 | 6484.50 | 152.58 | 298119.75 |
document location:
summary/3_1_circRNA_candidate_prediction/2_circRNA_expression_Statistics.xlsx
summary/3_1_circRNA_candidate_prediction/4_circRNA_expression_Boxplot.png
| Sample | 0-0.1 FI | 0.1-0.3 FI | 0.3-3.57 FI | 3.57-15 FI | 15-60 FI | >60 FI |
| EM01_M | 51(0.47%) | 160(1.47%) | 2719(24.94%) | 5196(47.65%) | 2193(20.11%) | 585(5.37%) |
| EM02_M | 38(0.35%) | 163(1.50%) | 2713(24.93%) | 5184(47.63%) | 2201(20.22%) | 584(5.37%) |
| EM03_M | 41(0.38%) | 159(1.46%) | 2722(25.01%) | 5175(47.55%) | 2201(20.22%) | 585(5.38%) |
| KTY01_K | 52(0.48%) | 146(1.34%) | 1792(16.45%) | 5143(47.22%) | 3130(28.74%) | 628(5.77%) |
| KTY02_K | 35(0.32%) | 129(1.18%) | 1872(17.16%) | 5252(48.16%) | 2995(27.46%) | 623(5.71%) |
| KTY03_K | 48(0.44%) | 145(1.33%) | 1786(16.41%) | 5137(47.19%) | 3139(28.84%) | 630(5.79%) |
document location: summary/3_1_circRNA_candidate_prediction/3_circRNA_expression_Interval.xlsx
document location: summary/3_1_circRNA_candidate_prediction/5_circRNA_expression_Density.pdf
| Accession | EM01_M_count | EM02_M_count | EM03_M_count | KTY01_K_count | KTY02_K_count | KTY03_K_count | EM01_M_fpkm | EM02_M_fpkm | EM03_M_fpkm | KTY01_K_fpkm | KTY02_K_fpkm | KTY03_K_fpkm | chr | start | end | strand | exon Count | circType | circRNA category | isoformName | geneName | hosting gene type | flankIntron | gene Discription | GO | KEGG |
| circRNA3141 | 158661.73 | 123826.27 | 125673.87 | 45535.35 | 67268.48 | 39112.54 | 22244.51 | 22269.28 | 22273.99 | 6462.67 | 9601.09 | 6484.50 | chr4 | 73413420 | 73413634 | + | 1 | circRNA | - | ENST00000295897 | ALB | mRNA | chr4:73412125-73413419|chr4:73413634-73415034 | albumin [Source:HGNC Symbol;Acc:HGNC:399] | GO:0001895(retina homeostasis);GO:0002576(platelet degranulation);GO:0003677(DNA binding);GO:0005504(fatty acid binding);GO:0005507(copper ion binding);GO:0005515(protein binding);GO:0005576(extracellular region);GO:0005615(extracellular space);GO:0005634(nucleus);GO:0005737(cytoplasm);GO:0006810(transport);GO:0006898(receptor-mediated endocytosis);GO:0007596(blood coagulation);GO:0008144(drug binding);GO:0008206(bile acid metabolic process);GO:0009267(cellular response to starvation);GO:0015643(toxic substance binding);GO:0015721(bile acid and bile salt transport);GO:0016209(antioxidant activity);GO:0019825(oxygen binding);GO:0019836(hemolysis by symbiont of host erythrocytes);GO:0030168(platelet activation);GO:0030170(pyridoxal phosphate binding);GO:0031093(platelet alpha granule lumen);GO:0042157(lipoprotein metabolic process);GO:0043066(negative regulation of apoptotic process);GO:0043069(negative regulation of programmed cell death);GO:0043209(myelin sheath);GO:0043234(protein complex);GO:0043252(sodium-independent organic anion transport);GO:0044281(small molecule metabolic process);GO:0051087(chaperone binding);GO:0051659(maintenance of mitochondrion location);GO:0055085(transmembrane transport);GO:0070062(extracellular exosome);GO:0072562(blood microparticle) | NA |
| circRNA3138 | 277243.25 | 216129.87 | 219354.84 | 91442.92 | 129764.18 | 77867.33 | 13181.38 | 13181.27 | 13184.07 | 4401.11 | 6280.77 | 4377.89 | chr4 | 73405116 | 73410409 | + | 5 | circRNA | - | ENST00000295897 | ALB | mRNA | chr4:73404406-73405115|chr4:73410409-73411995 | albumin [Source:HGNC Symbol;Acc:HGNC:399] | GO:0001895(retina homeostasis);GO:0002576(platelet degranulation);GO:0003677(DNA binding);GO:0005504(fatty acid binding);GO:0005507(copper ion binding);GO:0005515(protein binding);GO:0005576(extracellular region);GO:0005615(extracellular space);GO:0005634(nucleus);GO:0005737(cytoplasm);GO:0006810(transport);GO:0006898(receptor-mediated endocytosis);GO:0007596(blood coagulation);GO:0008144(drug binding);GO:0008206(bile acid metabolic process);GO:0009267(cellular response to starvation);GO:0015643(toxic substance binding);GO:0015721(bile acid and bile salt transport);GO:0016209(antioxidant activity);GO:0019825(oxygen binding);GO:0019836(hemolysis by symbiont of host erythrocytes);GO:0030168(platelet activation);GO:0030170(pyridoxal phosphate binding);GO:0031093(platelet alpha granule lumen);GO:0042157(lipoprotein metabolic process);GO:0043066(negative regulation of apoptotic process);GO:0043069(negative regulation of programmed cell death);GO:0043209(myelin sheath);GO:0043234(protein complex);GO:0043252(sodium-independent organic anion transport);GO:0044281(small molecule metabolic process);GO:0051087(chaperone binding);GO:0051659(maintenance of mitochondrion location);GO:0055085(transmembrane transport);GO:0070062(extracellular exosome);GO:0072562(blood microparticle) | NA |
| circRNA3140 | 98698.15 | 76937.94 | 78068.13 | 28333.61 | 40333.60 | 24250.76 | 13048.58 | 13047.81 | 13047.59 | 3792.00 | 5428.50 | 3791.31 | chr4 | 73410312 | 73412125 | + | 2 | circRNA | - | ENST00000295897 | ALB | mRNA | chr4:73409487-73410311|chr4:73412125-73413419 | albumin [Source:HGNC Symbol;Acc:HGNC:399] | GO:0001895(retina homeostasis);GO:0002576(platelet degranulation);GO:0003677(DNA binding);GO:0005504(fatty acid binding);GO:0005507(copper ion binding);GO:0005515(protein binding);GO:0005576(extracellular region);GO:0005615(extracellular space);GO:0005634(nucleus);GO:0005737(cytoplasm);GO:0006810(transport);GO:0006898(receptor-mediated endocytosis);GO:0007596(blood coagulation);GO:0008144(drug binding);GO:0008206(bile acid metabolic process);GO:0009267(cellular response to starvation);GO:0015643(toxic substance binding);GO:0015721(bile acid and bile salt transport);GO:0016209(antioxidant activity);GO:0019825(oxygen binding);GO:0019836(hemolysis by symbiont of host erythrocytes);GO:0030168(platelet activation);GO:0030170(pyridoxal phosphate binding);GO:0031093(platelet alpha granule lumen);GO:0042157(lipoprotein metabolic process);GO:0043066(negative regulation of apoptotic process);GO:0043069(negative regulation of programmed cell death);GO:0043209(myelin sheath);GO:0043234(protein complex);GO:0043252(sodium-independent organic anion transport);GO:0044281(small molecule metabolic process);GO:0051087(chaperone binding);GO:0051659(maintenance of mitochondrion location);GO:0055085(transmembrane transport);GO:0070062(extracellular exosome);GO:0072562(blood microparticle) | NA |
| circRNA7977 | 281141.58 | 218906.18 | 222141.70 | 88623.80 | 126458.70 | 75495.95 | 12003.55 | 11989.06 | 11989.94 | 3830.43 | 5496.57 | 3811.69 | chr4 | 73406629 | 73412125 | + | 5 | circRNA | - | ENST00000295897 | ALB | mRNA | chr4:73405173-73406628|chr4:73412125-73413419 | albumin [Source:HGNC Symbol;Acc:HGNC:399] | GO:0001895(retina homeostasis);GO:0002576(platelet degranulation);GO:0003677(DNA binding);GO:0005504(fatty acid binding);GO:0005507(copper ion binding);GO:0005515(protein binding);GO:0005576(extracellular region);GO:0005615(extracellular space);GO:0005634(nucleus);GO:0005737(cytoplasm);GO:0006810(transport);GO:0006898(receptor-mediated endocytosis);GO:0007596(blood coagulation);GO:0008144(drug binding);GO:0008206(bile acid metabolic process);GO:0009267(cellular response to starvation);GO:0015643(toxic substance binding);GO:0015721(bile acid and bile salt transport);GO:0016209(antioxidant activity);GO:0019825(oxygen binding);GO:0019836(hemolysis by symbiont of host erythrocytes);GO:0030168(platelet activation);GO:0030170(pyridoxal phosphate binding);GO:0031093(platelet alpha granule lumen);GO:0042157(lipoprotein metabolic process);GO:0043066(negative regulation of apoptotic process);GO:0043069(negative regulation of programmed cell death);GO:0043209(myelin sheath);GO:0043234(protein complex);GO:0043252(sodium-independent organic anion transport);GO:0044281(small molecule metabolic process);GO:0051087(chaperone binding);GO:0051659(maintenance of mitochondrion location);GO:0055085(transmembrane transport);GO:0070062(extracellular exosome);GO:0072562(blood microparticle) | NA |
| circRNA3139 | 120996.48 | 94296.50 | 95696.57 | 36874.72 | 54306.35 | 31609.33 | 10571.65 | 10568.38 | 10569.85 | 3261.46 | 4830.35 | 3265.84 | chr4 | 73408594 | 73409487 | + | 2 | circRNA | - | ENST00000295897 | ALB | mRNA | chr4:73406761-73408593|chr4:73409487-73410311 | albumin [Source:HGNC Symbol;Acc:HGNC:399] | GO:0001895(retina homeostasis);GO:0002576(platelet degranulation);GO:0003677(DNA binding);GO:0005504(fatty acid binding);GO:0005507(copper ion binding);GO:0005515(protein binding);GO:0005576(extracellular region);GO:0005615(extracellular space);GO:0005634(nucleus);GO:0005737(cytoplasm);GO:0006810(transport);GO:0006898(receptor-mediated endocytosis);GO:0007596(blood coagulation);GO:0008144(drug binding);GO:0008206(bile acid metabolic process);GO:0009267(cellular response to starvation);GO:0015643(toxic substance binding);GO:0015721(bile acid and bile salt transport);GO:0016209(antioxidant activity);GO:0019825(oxygen binding);GO:0019836(hemolysis by symbiont of host erythrocytes);GO:0030168(platelet activation);GO:0030170(pyridoxal phosphate binding);GO:0031093(platelet alpha granule lumen);GO:0042157(lipoprotein metabolic process);GO:0043066(negative regulation of apoptotic process);GO:0043069(negative regulation of programmed cell death);GO:0043209(myelin sheath);GO:0043234(protein complex);GO:0043252(sodium-independent organic anion transport);GO:0044281(small molecule metabolic process);GO:0051087(chaperone binding);GO:0051659(maintenance of mitochondrion location);GO:0055085(transmembrane transport);GO:0070062(extracellular exosome);GO:0072562(blood microparticle) | NA |
| ciRNA411 | 34528.05 | 26919.93 | 27308.26 | 29899.78 | 26304.89 | 25769.68 | 5847.11 | 5847.71 | 5846.09 | 5125.66 | 4534.86 | 5160.45 | chr4 | 154586608 | 154586785 | - | 1 | ciRNA | - | ENST00000622532 | FGA | mRNA | chr4:154585710-154586785 | fibrinogen alpha chain [Source:HGNC Symbol;Acc:HGNC:3661] | GO:0002576(platelet degranulation);GO:0005102(receptor binding);GO:0005198(structural molecule activity);GO:0005515(protein binding);GO:0005576(extracellular region);GO:0005577(fibrinogen complex);GO:0005615(extracellular space);GO:0005737(cytoplasm);GO:0005791(rough endoplasmic reticulum);GO:0005886(plasma membrane);GO:0005938(cell cortex);GO:0006461(protein complex assembly);GO:0006953(acute-phase response);GO:0007160(cell-matrix adhesion);GO:0007165(signal transduction);GO:0007596(blood coagulation);GO:0009897(external side of plasma membrane);GO:0009986(cell surface);GO:0030168(platelet activation);GO:0030198(extracellular matrix organization);GO:0030674(protein binding, bridging);GO:0031091(platelet alpha granule);GO:0031093(platelet alpha granule lumen);GO:0031639(plasminogen activation);GO:0032355(response to estradiol);GO:0033595(response to genistein);GO:0034116(positive regulation of heterotypic cell-cell adhesion);GO:0042730(fibrinolysis);GO:0043152(induction of bacterial agglutination);GO:0043278(response to morphine);GO:0043623(cellular protein complex assembly);GO:0045087(innate immune response);GO:0045907(positive regulation of vasoconstriction);GO:0045921(positive regulation of exocytosis);GO:0046898(response to cycloheximide);GO:0050714(positive regulation of protein secretion);GO:0050839(cell adhesion molecule binding);GO:0051258(protein polymerization);GO:0051592(response to calcium ion);GO:0070062(extracellular exosome);GO:0070374(positive regulation of ERK1 and ERK2 cascade);GO:0070527(platelet aggregation);GO:0071345(cellular response to cytokine stimulus);GO:0071354(cellular response to interleukin-6);GO:0071407(cellular response to organic cyclic compound);GO:0072377(blood coagulation, common pathway);GO:0072378(blood coagulation, fibrin clot formation);GO:0072562(blood microparticle);GO:0090277(positive regulation of peptide hormone secretion);GO:0097421(liver regeneration);GO:1900026(positive regulation of substrate adhesion-dependent cell spreading);GO:1902042(negative regulation of extrinsic apoptotic signaling pathway via death domain receptors);GO:1903561(extracellular vesicle);GO:1990643(cellular response to granulocyte colony-stimulating factor);GO:2000261(negative regulation of blood coagulation, common pathway);GO:2000352(negative regulation of endothelial cell apoptotic process) | 04610(Complement and coagulation cascades) |
| circRNA8056 | 85425.09 | 67015.66 | 68037.66 | 71242.13 | 61734.78 | 61437.29 | 3949.36 | 3974.30 | 3976.43 | 3334.20 | 2905.56 | 3358.79 | chr4 | 154566489 | 154569307 | + | 4 | circRNA | - | ENST00000302068 | FGB | mRNA | chr4:154565999-154566488|chr4:154569307-154569513 | fibrinogen beta chain [Source:HGNC Symbol;Acc:HGNC:3662] | GO:0002576(platelet degranulation);GO:0005102(receptor binding);GO:0005198(structural molecule activity);GO:0005515(protein binding);GO:0005576(extracellular region);GO:0005577(fibrinogen complex);GO:0005615(extracellular space);GO:0005737(cytoplasm);GO:0005886(plasma membrane);GO:0005938(cell cortex);GO:0007160(cell-matrix adhesion);GO:0007165(signal transduction);GO:0007596(blood coagulation);GO:0009897(external side of plasma membrane);GO:0009986(cell surface);GO:0030168(platelet activation);GO:0030198(extracellular matrix organization);GO:0030674(protein binding, bridging);GO:0031091(platelet alpha granule);GO:0031093(platelet alpha granule lumen);GO:0031639(plasminogen activation);GO:0034116(positive regulation of heterotypic cell-cell adhesion);GO:0042730(fibrinolysis);GO:0043152(induction of bacterial agglutination);GO:0043623(cellular protein complex assembly);GO:0044320(cellular response to leptin stimulus);GO:0045087(innate immune response);GO:0045907(positive regulation of vasoconstriction);GO:0045921(positive regulation of exocytosis);GO:0050714(positive regulation of protein secretion);GO:0050839(cell adhesion molecule binding);GO:0051087(chaperone binding);GO:0051258(protein polymerization);GO:0051592(response to calcium ion);GO:0070062(extracellular exosome);GO:0070374(positive regulation of ERK1 and ERK2 cascade);GO:0070527(platelet aggregation);GO:0071347(cellular response to interleukin-1);GO:0072378(blood coagulation, fibrin clot formation);GO:0072562(blood microparticle);GO:0090277(positive regulation of peptide hormone secretion);GO:1900026(positive regulation of substrate adhesion-dependent cell spreading);GO:1902042(negative regulation of extrinsic apoptotic signaling pathway via death domain receptors);GO:1903561(extracellular vesicle);GO:2000352(negative regulation of endothelial cell apoptotic process) | NA |
| circRNA8267 | 23775.78 | 18355.53 | 18633.03 | 31391.58 | 28550.58 | 26783.58 | 3791.95 | 3755.23 | 3756.76 | 5068.19 | 4635.54 | 5051.33 | chr3 | 133764875 | 133766433 | + | 2 | circRNA | - | ENST00000402696 | TF | mRNA | chr3:133764275-133764874|chr3:133766433-133768028 | transferrin [Source:HGNC Symbol;Acc:HGNC:11740] | GO:0001895(retina homeostasis);GO:0002576(platelet degranulation);GO:0005102(receptor binding);GO:0005515(protein binding);GO:0005576(extracellular region);GO:0005615(extracellular space);GO:0005769(early endosome);GO:0005770(late endosome);GO:0005905(coated pit);GO:0006826(iron ion transport);GO:0006879(cellular iron ion homeostasis);GO:0007596(blood coagulation);GO:0008199(ferric iron binding);GO:0009925(basal plasma membrane);GO:0009986(cell surface);GO:0010008(endosome membrane);GO:0015091(ferric iron transmembrane transporter activity);GO:0016023(cytoplasmic membrane-bounded vesicle);GO:0016324(apical plasma membrane);GO:0030139(endocytic vesicle);GO:0030168(platelet activation);GO:0031982(vesicle);GO:0033572(transferrin transport);GO:0034774(secretory granule lumen);GO:0045178(basal part of cell);GO:0048471(perinuclear region of cytoplasm);GO:0055037(recycling endosome);GO:0055085(transmembrane transport);GO:0070062(extracellular exosome);GO:0072562(blood microparticle) | 04978(Mineral absorption) |
| circRNA518 | 15959.64 | 12428.64 | 12608.64 | 1970.50 | 1997.50 | 1682.50 | 3644.50 | 3640.67 | 3639.87 | 455.52 | 464.37 | 454.34 | chr11 | 6437046 | 6437177 | - | 1 | circRNA | - | ENST00000265983 | HPX | mRNA | chr11:6432017-6437045|chr11:6437177-6437439 | hemopexin [Source:HGNC Symbol;Acc:HGNC:5171] | GO:0002639(positive regulation of immunoglobulin production);GO:0002925(positive regulation of humoral immune response mediated by circulating immunoglobulin);GO:0005515(protein binding);GO:0005576(extracellular region);GO:0005615(extracellular space);GO:0006879(cellular iron ion homeostasis);GO:0006898(receptor-mediated endocytosis);GO:0015232(heme transporter activity);GO:0015886(heme transport);GO:0016032(viral process);GO:0020027(hemoglobin metabolic process);GO:0042168(heme metabolic process);GO:0042511(positive regulation of tyrosine phosphorylation of Stat1 protein);GO:0046872(metal ion binding);GO:0051246(regulation of protein metabolic process);GO:0060332(positive regulation of response to interferon-gamma);GO:0060335(positive regulation of interferon-gamma-mediated signaling pathway);GO:0070062(extracellular exosome);GO:0071682(endocytic vesicle lumen);GO:0072562(blood microparticle) | NA |
| circRNA3490 | 112253.47 | 87333.60 | 88656.35 | 134997.33 | 126292.75 | 115913.50 | 3481.15 | 3474.14 | 3475.64 | 4238.00 | 3987.12 | 4250.76 | chr3 | 133754495 | 133764275 | + | 7 | circRNA | - | ENST00000402696 | TF | mRNA | chr3:133753703-133754494|chr3:133764275-133764874 | transferrin [Source:HGNC Symbol;Acc:HGNC:11740] | GO:0001895(retina homeostasis);GO:0002576(platelet degranulation);GO:0005102(receptor binding);GO:0005515(protein binding);GO:0005576(extracellular region);GO:0005615(extracellular space);GO:0005769(early endosome);GO:0005770(late endosome);GO:0005905(coated pit);GO:0006826(iron ion transport);GO:0006879(cellular iron ion homeostasis);GO:0007596(blood coagulation);GO:0008199(ferric iron binding);GO:0009925(basal plasma membrane);GO:0009986(cell surface);GO:0010008(endosome membrane);GO:0015091(ferric iron transmembrane transporter activity);GO:0016023(cytoplasmic membrane-bounded vesicle);GO:0016324(apical plasma membrane);GO:0030139(endocytic vesicle);GO:0030168(platelet activation);GO:0031982(vesicle);GO:0033572(transferrin transport);GO:0034774(secretory granule lumen);GO:0045178(basal part of cell);GO:0048471(perinuclear region of cytoplasm);GO:0055037(recycling endosome);GO:0055085(transmembrane transport);GO:0070062(extracellular exosome);GO:0072562(blood microparticle) | 04978(Mineral absorption) |
| circRNA9803 | 16902.10 | 13192.33 | 13362.67 | 3519.40 | 6512.54 | 3022.05 | 3245.12 | 3249.03 | 3243.28 | 684.02 | 1272.91 | 686.12 | chr11 | 116837001 | 116837157 | - | 1 | circRNA | - | ENST00000375320 | APOA1 | mRNA | chr11:116836411-116837000|chr11:116837157-116837344 | apolipoprotein A-I [Source:HGNC Symbol;Acc:HGNC:600] | GO:0001523(retinoid metabolic process);GO:0001540(beta-amyloid binding);GO:0001932(regulation of protein phosphorylation);GO:0001935(endothelial cell proliferation);GO:0002576(platelet degranulation);GO:0002740(negative regulation of cytokine secretion involved in immune response);GO:0005319(lipid transporter activity);GO:0005515(protein binding);GO:0005543(phospholipid binding);GO:0005548(phospholipid transporter activity);GO:0005576(extracellular region);GO:0005615(extracellular space);GO:0005634(nucleus);GO:0005769(early endosome);GO:0005788(endoplasmic reticulum lumen);GO:0005829(cytosol);GO:0005886(plasma membrane);GO:0006644(phospholipid metabolic process);GO:0006656(phosphatidylcholine biosynthetic process);GO:0006695(cholesterol biosynthetic process);GO:0006869(lipid transport);GO:0006898(receptor-mediated endocytosis);GO:0007186(G-protein coupled receptor signaling pathway);GO:0007229(integrin-mediated signaling pathway);GO:0007584(response to nutrient);GO:0007596(blood coagulation);GO:0007603(phototransduction, visible light);GO:0008035(high-density lipoprotein particle binding);GO:0008203(cholesterol metabolic process);GO:0008211(glucocorticoid metabolic process);GO:0008289(lipid binding);GO:0009986(cell surface);GO:0010804(negative regulation of tumor necrosis factor-mediated signaling pathway);GO:0010873(positive regulation of cholesterol esterification);GO:0010898(positive regulation of triglyceride catabolic process);GO:0010903(negative regulation of very-low-density lipoprotein particle remodeling);GO:0014012(peripheral nervous system axon regeneration);GO:0015485(cholesterol binding);GO:0015914(phospholipid transport);GO:0017127(cholesterol transporter activity);GO:0018158(protein oxidation);GO:0018206(peptidyl-methionine modification);GO:0019433(triglyceride catabolic process);GO:0019899(enzyme binding);GO:0019915(lipid storage);GO:0030139(endocytic vesicle);GO:0030168(platelet activation);GO:0030300(regulation of intestinal cholesterol absorption);GO:0030301(cholesterol transport);GO:0030325(adrenal gland development);GO:0031100(organ regeneration);GO:0031102(neuron projection regeneration);GO:0031210(phosphatidylcholine binding);GO:0031410(cytoplasmic vesicle);GO:0032489(regulation of Cdc42 protein signal transduction);GO:0033344(cholesterol efflux);GO:0033700(phospholipid efflux);GO:0034115(negative regulation of heterotypic cell-cell adhesion);GO:0034190(apolipoprotein receptor binding);GO:0034191(apolipoprotein A-I receptor binding);GO:0034361(very-low-density lipoprotein particle);GO:0034364(high-density lipoprotein particle);GO:0034365(discoidal high-density lipoprotein particle);GO:0034366(spherical high-density lipoprotein particle);GO:0034372(very-low-density lipoprotein particle remodeling);GO:0034375(high-density lipoprotein particle remodeling);GO:0034380(high-density lipoprotein particle assembly);GO:0034384(high-density lipoprotein particle clearance);GO:0034774(secretory granule lumen);GO:0035025(positive regulation of Rho protein signal transduction);GO:0042157(lipoprotein metabolic process);GO:0042158(lipoprotein biosynthetic process);GO:0042493(response to drug);GO:0042627(chylomicron);GO:0042632(cholesterol homeostasis);GO:0042802(identical protein binding);GO:0043534(blood vessel endothelial cell migration);GO:0043627(response to estrogen);GO:0043691(reverse cholesterol transport);GO:0044255(cellular lipid metabolic process);GO:0044281(small molecule metabolic process);GO:0045499(chemorepellent activity);GO:0045723(positive regulation of fatty acid biosynthetic process);GO:0050713(negative regulation of interleukin-1 beta secretion);GO:0050728(negative regulation of inflammatory response);GO:0050821(protein stabilization);GO:0050919(negative chemotaxis);GO:0051006(positive regulation of lipoprotein lipase activity);GO:0051180(vitamin transport);GO:0051345(positive regulation of hydrolase activity);GO:0051346(negative regulation of hydrolase activity);GO:0051496(positive regulation of stress fiber assembly);GO:0055085(transmembrane transport);GO:0055091(phospholipid homeostasis);GO:0055102(lipase inhibitor activity);GO:0060192(negative regulation of lipase activity);GO:0060228(phosphatidylcholine-sterol O-acyltransferase activator activity);GO:0060354(negative regulation of cell adhesion molecule production);GO:0060761(negative regulation of response to cytokine stimulus);GO:0070062(extracellular exosome);GO:0070328(triglyceride homeostasis);GO:0070508(cholesterol import);GO:0070653(high-density lipoprotein particle receptor binding);GO:0071682(endocytic vesicle lumen);GO:0071813(lipoprotein particle binding);GO:0072562(blood microparticle);GO:1900026(positive regulation of substrate adhesion-dependent cell spreading);GO:1903561(extracellular vesicle) | 03320(PPAR signaling pathway);04975(Fat digestion and absorption);04977(Vitamin digestion and absorption);05143(African trypanosomiasis) |
| circRNA9953 | 24555.31 | 19255.78 | 19529.78 | 18404.62 | 36059.82 | 15760.12 | 2761.85 | 2778.16 | 2776.86 | 2095.53 | 4128.92 | 2096.15 | chr14 | 94378373 | 94378640 | - | 1 | circRNA | - | ENST00000489769 | SERPINA1 | mRNA | None|chr14:94378640-94379463 | serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 [Source:HGNC Symbol;Acc:HGNC:8941] | NA | NA |
| circRNA914 | 28624.46 | 22280.80 | 22596.44 | 14096.65 | 13313.98 | 12099.58 | 2696.35 | 2692.23 | 2690.80 | 1344.21 | 1276.75 | 1347.78 | chr10 | 93593823 | 93600499 | - | 2 | circRNA | - | ENST00000371464 | RBP4 | mRNA | chr10:93592112-93593822|chr10:93600499-93600666 | retinol binding protein 4, plasma [Source:HGNC Symbol;Acc:HGNC:9922] | GO:0001523(retinoid metabolic process);GO:0001654(eye development);GO:0005215(transporter activity);GO:0005501(retinoid binding);GO:0005515(protein binding);GO:0005576(extracellular region);GO:0005615(extracellular space);GO:0005829(cytosol);GO:0006094(gluconeogenesis);GO:0006810(transport);GO:0007507(heart development);GO:0007603(phototransduction, visible light);GO:0016918(retinal binding);GO:0019841(retinol binding);GO:0030277(maintenance of gastrointestinal epithelium);GO:0030324(lung development);GO:0032024(positive regulation of insulin secretion);GO:0032526(response to retinoic acid);GO:0034632(retinol transporter activity);GO:0034633(retinol transport);GO:0036094(small molecule binding);GO:0042572(retinol metabolic process);GO:0042593(glucose homeostasis);GO:0043234(protein complex);GO:0045471(response to ethanol);GO:0046982(protein heterodimerization activity);GO:0048562(embryonic organ morphogenesis);GO:0048706(embryonic skeletal system development);GO:0048738(cardiac muscle tissue development);GO:0048807(female genitalia morphogenesis);GO:0051024(positive regulation of immunoglobulin secretion);GO:0060044(negative regulation of cardiac muscle cell proliferation);GO:0060059(embryonic retina morphogenesis in camera-type eye);GO:0060065(uterus development);GO:0060068(vagina development);GO:0060157(urinary bladder development);GO:0060347(heart trabecula formation);GO:0070062(extracellular exosome) | NA |
| circRNA3304 | 31785.69 | 24860.55 | 25229.30 | 8070.71 | 7570.79 | 6664.47 | 2661.45 | 2670.18 | 2670.51 | 684.09 | 645.34 | 659.87 | chr3 | 15735410 | 15751820 | - | 3 | circRNA | - | ENST00000383777 | ANKRD28 | mRNA | chr3:15724524-15735409|chr3:15751820-15756483 | ankyrin repeat domain 28 [Source:HGNC Symbol;Acc:HGNC:29024] | GO:0005515(protein binding);GO:0005654(nucleoplasm) | NA |
| ciRNA32 | 13250.77 | 10387.11 | 10547.11 | 3017.67 | 5545.35 | 2577.57 | 2645.17 | 2659.80 | 2661.63 | 609.81 | 1126.94 | 608.46 | chr11 | 116836240 | 116836390 | + | 1 | ciRNA | antisense | ENST00000444200 | APOA1-AS | lncRNA | chr11:116836239-116855289 | NA | NA | NA |
| circRNA913 | 17707.28 | 13766.63 | 13976.13 | 8083.08 | 7611.48 | 6932.08 | 2505.89 | 2499.08 | 2500.34 | 1157.98 | 1096.57 | 1160.07 | chr10 | 93593823 | 93594035 | - | 1 | circRNA | - | ENST00000371464 | RBP4 | mRNA | chr10:93592112-93593822|chr10:93594035-93600392 | retinol binding protein 4, plasma [Source:HGNC Symbol;Acc:HGNC:9922] | GO:0001523(retinoid metabolic process);GO:0001654(eye development);GO:0005215(transporter activity);GO:0005501(retinoid binding);GO:0005515(protein binding);GO:0005576(extracellular region);GO:0005615(extracellular space);GO:0005829(cytosol);GO:0006094(gluconeogenesis);GO:0006810(transport);GO:0007507(heart development);GO:0007603(phototransduction, visible light);GO:0016918(retinal binding);GO:0019841(retinol binding);GO:0030277(maintenance of gastrointestinal epithelium);GO:0030324(lung development);GO:0032024(positive regulation of insulin secretion);GO:0032526(response to retinoic acid);GO:0034632(retinol transporter activity);GO:0034633(retinol transport);GO:0036094(small molecule binding);GO:0042572(retinol metabolic process);GO:0042593(glucose homeostasis);GO:0043234(protein complex);GO:0045471(response to ethanol);GO:0046982(protein heterodimerization activity);GO:0048562(embryonic organ morphogenesis);GO:0048706(embryonic skeletal system development);GO:0048738(cardiac muscle tissue development);GO:0048807(female genitalia morphogenesis);GO:0051024(positive regulation of immunoglobulin secretion);GO:0060044(negative regulation of cardiac muscle cell proliferation);GO:0060059(embryonic retina morphogenesis in camera-type eye);GO:0060065(uterus development);GO:0060068(vagina development);GO:0060157(urinary bladder development);GO:0060347(heart trabecula formation);GO:0070062(extracellular exosome) | NA |
| ciRNA257 | 13823.97 | 10832.45 | 10999.78 | 3109.75 | 5749.02 | 2654.90 | 2495.20 | 2508.08 | 2509.91 | 568.21 | 1056.39 | 566.67 | chr11 | 116836240 | 116836406 | + | 1 | ciRNA | antisense | ENST00000444200 | APOA1-AS | lncRNA | chr11:116836239-116855289 | NA | NA | NA |
| ciRNA34 | 13911.97 | 10903.61 | 11071.78 | 3120.75 | 5791.35 | 2664.90 | 2481.37 | 2494.68 | 2496.45 | 563.47 | 1051.58 | 562.07 | chr11 | 116836240 | 116836408 | + | 1 | ciRNA | antisense | ENST00000444200 | APOA1-AS | lncRNA | chr11:116836239-116855289 | NA | NA | NA |
| ciRNA33 | 13998.97 | 10971.11 | 11139.28 | 3137.25 | 5837.85 | 2678.90 | 2467.68 | 2480.77 | 2482.29 | 559.83 | 1047.62 | 558.42 | chr11 | 116836240 | 116836410 | + | 1 | ciRNA | antisense | ENST00000444200 | APOA1-AS | lncRNA | chr11:116836239-116855289 | NA | NA | NA |
document location: summary/3_1_circRNA_candidate_prediction/1_circRNA_expression.xlsx
Those reads in sequencing rawdata with back splicing junctions (BSJ) of circRNA could be identified by tophat-fusion and CIRCExplorer. We calculated BSJ of each circRNA and those circRNAs with amount of BSJ were priority to run qRT-PCR.
| Accession | circRNA_size | chr | start | end | strand | EM01_M_backsplice_reads | EM02_M_backsplice_reads | EM03_M_backsplice_reads | KTY01_K_backsplice_reads | KTY02_K_backsplice_reads | KTY03_K_backsplice_reads |
| circRNA15842 | 501 | chr4 | 116451248 | 116506377 | - | 8591 | 7508 | 157 | 0 | 0 | 0 |
| circRNA19240 | 416 | chr1 | 12020783 | 12036588 | - | 2608 | 3255 | 255 | 0 | 0 | 0 |
| circRNA9353 | 804 | chr18 | 21563331 | 21583174 | - | 2332 | 3343 | 51 | 589 | 2 | 1 |
| circRNA6659 | 425 | chr15 | 2501282 | 2502717 | + | 1956 | 4091 | 211 | 1468 | 37 | 33 |
| circRNA17547 | 247 | chr2 | 670645 | 682819 | - | 1709 | 3206 | 151 | 1626 | 20 | 35 |
| circRNA9837 | 415 | chr18 | 69228999 | 69241376 | + | 1485 | 1429 | 47 | 331 | 4 | 0 |
| circRNA15546 | 576 | chr4 | 61096545 | 61117489 | + | 1478 | 392 | 29 | 118 | 0 | 0 |
| circRNA2336 | 656 | chr12 | 116657499 | 116660259 | + | 1356 | 996 | 43 | 578 | 4 | 2 |
| circRNA16757 | 347 | chr3 | 84813931 | 84819571 | + | 1349 | 1756 | 80 | 1018 | 4 | 2 |
| circRNA21595 | 457 | chr9 | 136497 | 178236 | + | 1349 | 1778 | 41 | 455 | 6 | 7 |
| circRNA8799 | 290 | chr19 | 8688359 | 8689713 | - | 1260 | 2211 | 178 | 206 | 4 | 5 |
| circRNA2251 | 1117 | chr12 | 99634398 | 99635514 | - | 1066 | 265 | 11 | 88 | 0 | 0 |
| circRNA22513 | 510 | chr9 | 100620061 | 100628977 | - | 1034 | 1836 | 113 | 694 | 10 | 9 |
| circRNA7959 | 1099 | chr14 | 34157914 | 34159012 | - | 995 | 53 | 6 | 105 | 0 | 1 |
| circRNA23227 | 432 | chr8 | 68352298 | 68362771 | + | 945 | 1618 | 48 | 295 | 4 | 7 |
| circRNA1751 | 944 | chr12 | 55328898 | 55353601 | - | 944 | 149 | 19 | 0 | 0 | 0 |
| circRNA23515 | 261 | chr8 | 106589098 | 106613428 | + | 934 | 1586 | 319 | 113 | 4 | 6 |
| circRNA19753 | 376 | chr1 | 55919393 | 55934687 | - | 919 | 657 | 29 | 252 | 0 | 0 |
| circRNA15550 | 447 | chr4 | 61110615 | 61117489 | + | 917 | 769 | 45 | 519 | 3 | 5 |
| circRNA2334 | 946 | chr12 | 116657499 | 116706207 | + | 861 | 361 | 10 | 357 | 0 | 0 |
| circRNA969 | 1832 | chr13 | 70113153 | 70114984 | + | 779 | 40 | 13 | 20 | 0 | 0 |
| circRNA9256 | 549 | chr18 | 1045380 | 1130355 | - | 735 | 275 | 55 | 436 | 1 | 2 |
| circRNA13594 | 394 | chr6 | 142236513 | 142257371 | + | 723 | 1354 | 59 | 168 | 0 | 0 |
| circRNA18188 | 981 | chr2 | 88324511 | 88325491 | + | 720 | 146 | 11 | 31 | 0 | 0 |
| circRNA23718 | 640 | chr8 | 142706465 | 142707104 | - | 718 | 248 | 29 | 256 | 0 | 3 |
| circRNA687 | 390 | chr13 | 37155673 | 37171081 | + | 710 | 703 | 109 | 107 | 5 | 2 |
| circRNA9268 | 220 | chr18 | 1103568 | 1130355 | - | 683 | 1598 | 139 | 614 | 9 | 10 |
| circRNA22882 | 448 | chr8 | 18827625 | 18833177 | - | 670 | 811 | 28 | 300 | 0 | 0 |
| circRNA10915 | 1131 | chr7 | 18616505 | 18617635 | + | 659 | 164 | 3 | 228 | 2 | 1 |
| circRNA16222 | 667 | chr4 | 166132077 | 166132743 | - | 652 | 779 | 40 | 489 | 1 | 0 |
| circRNA18186 | 1044 | chr2 | 88317772 | 88325491 | + | 637 | 186 | 4 | 25 | 0 | 0 |
| circRNA23517 | 380 | chr8 | 106589098 | 106741924 | + | 599 | 747 | 130 | 29 | 0 | 4 |
| circRNA18953 | 666 | chr2 | 160278475 | 160285829 | - | 591 | 151 | 32 | 70 | 0 | 0 |
| circRNA19246 | 1399 | chr1 | 12020783 | 12117310 | - | 578 | 354 | 7 | 0 | 0 | 0 |
| circRNA20543 | 484 | chr1 | 131741537 | 131770438 | - | 567 | 189 | 21 | 137 | 0 | 0 |
| circRNA10352 | 486 | chr20 | 34366126 | 34376167 | - | 554 | 395 | 45 | 1 | 0 | 0 |
| circRNA3096 | 380 | chr11 | 51895232 | 51896107 | + | 543 | 6 | 0 | 166 | 0 | 0 |
| circRNA3546 | 382 | chr11 | 112817857 | 112825899 | + | 539 | 483 | 31 | 29 | 2 | 3 |
| circRNA13367 | 488 | chr6 | 127964702 | 127969726 | + | 533 | 438 | 10 | 0 | 0 | 0 |
| circRNA9265 | 315 | chr18 | 1082527 | 1130355 | - | 532 | 733 | 133 | 572 | 12 | 10 |
| circRNA21926 | 500 | chr9 | 31989663 | 32066590 | + | 521 | 145 | 36 | 98 | 1 | 0 |
| circRNA10386 | 554 | chr20 | 35948547 | 35972733 | + | 515 | 707 | 28 | 152 | 1 | 0 |
| circRNA22134 | 949 | chr9 | 60742635 | 60747444 | - | 507 | 63 | 10 | 8 | 0 | 0 |
| circRNA9689 | 679 | chr18 | 60525605 | 60539712 | - | 499 | 102 | 66 | 183 | 13 | 21 |
| circRNA14807 | 488 | chr5 | 147122690 | 147148995 | + | 492 | 712 | 36 | 47 | 3 | 0 |
| circRNA15749 | 428 | chr4 | 98285534 | 98285961 | - | 492 | 240 | 44 | 105 | 0 | 6 |
| circRNA17606 | 405 | chr2 | 4284990 | 4293199 | - | 479 | 633 | 57 | 11 | 54 | 40 |
| circRNA23077 | 201 | chr8 | 42612111 | 42612631 | - | 479 | 1293 | 276 | 0 | 25 | 53 |
| circRNA4843 | 258 | chr10 | 90341403 | 90343551 | + | 478 | 971 | 81 | 413 | 8 | 5 |
| circRNA19255 | 1303 | chr1 | 12034271 | 12117310 | - | 475 | 261 | 1 | 0 | 0 | 0 |
| circRNA18671 | 402 | chr2 | 123095051 | 123108802 | - | 466 | 429 | 31 | 201 | 0 | 4 |
| circRNA9884 | 815 | chr18 | 70722809 | 70735454 | - | 460 | 614 | 20 | 94 | 0 | 0 |
| circRNA11744 | 496 | chr7 | 82204583 | 82205078 | - | 454 | 631 | 38 | 767 | 16 | 5 |
| circRNA11767 | 440 | chr7 | 84781106 | 84785375 | - | 454 | 522 | 30 | 350 | 0 | 3 |
| circRNA12533 | 345 | chr7 | 169127737 | 169146657 | - | 445 | 417 | 28 | 80 | 0 | 2 |
| circRNA8621 | 290 | chr14 | 117109536 | 117111520 | + | 439 | 636 | 127 | 11 | 2 | 7 |
| circRNA13077 | 522 | chr6 | 77734712 | 77753899 | - | 437 | 449 | 19 | 67 | 8 | 1 |
| circRNA23205 | 219 | chr8 | 62769108 | 62772652 | - | 436 | 522 | 92 | 437 | 0 | 5 |
| circRNA14850 | 620 | chr5 | 151646756 | 151647970 | - | 432 | 129 | 25 | 482 | 0 | 0 |
| circRNA17065 | 449 | chr3 | 134485312 | 134493497 | - | 428 | 311 | 18 | 154 | 3 | 2 |
| circRNA15845 | 549 | chr4 | 116531006 | 116534131 | - | 424 | 288 | 16 | 0 | 1 | 3 |
| circRNA18576 | 410 | chr2 | 112585277 | 112592876 | + | 421 | 185 | 58 | 108 | 1 | 2 |
| circRNA11302 | 874 | chr7 | 41946381 | 41947254 | + | 420 | 542 | 65 | 509 | 5 | 10 |
| circRNA13475 | 572 | chr6 | 135263124 | 135263695 | + | 420 | 185 | 39 | 40 | 3 | 1 |
| circRNA9919 | 259 | chr18 | 73350906 | 73352264 | + | 419 | 376 | 47 | 244 | 0 | 2 |
| circRNA7547 | 556 | chr15 | 107531899 | 107560230 | + | 417 | 294 | 16 | 292 | 0 | 0 |
| circRNA17628 | 684 | chr2 | 8855092 | 8855775 | - | 413 | 606 | 4 | 110 | 0 | 0 |
| circRNA21009 | 360 | chr1 | 186630443 | 186635255 | + | 404 | 746 | 27 | 45 | 0 | 1 |
| circRNA8065 | 300 | chr14 | 53450374 | 53451762 | + | 403 | 230 | 56 | 242 | 7 | 8 |
| circRNA15033 | 502 | chr4 | 255609 | 288290 | - | 389 | 612 | 42 | 5 | 0 | 0 |
| circRNA9842 | 519 | chr18 | 69264556 | 69295610 | + | 389 | 401 | 25 | 71 | 2 | 2 |
| circRNA10023 | 436 | chr20 | 4490356 | 4491281 | - | 381 | 490 | 28 | 601 | 4 | 4 |
| circRNA18823 | 683 | chr2 | 146808447 | 146826014 | + | 376 | 324 | 30 | 191 | 8 | 8 |
| circRNA5148 | 363 | chr17 | 21003976 | 21012138 | - | 367 | 327 | 5 | 15 | 0 | 0 |
| circRNA2724 | 354 | chr11 | 22539660 | 22552736 | - | 360 | 754 | 18 | 5 | 2 | 1 |
| circRNA13766 | 680 | chr6 | 173603642 | 173611928 | + | 358 | 107 | 24 | 20 | 2 | 0 |
| circRNA23703 | 315 | chr8 | 142313534 | 142341009 | - | 352 | 340 | 19 | 79 | 1 | 0 |
| circRNA18070 | 505 | chr2 | 74343695 | 74356788 | - | 350 | 266 | 1 | 119 | 1 | 0 |
| circRNA11367 | 462 | chr7 | 44881245 | 44886252 | - | 349 | 612 | 19 | 268 | 6 | 2 |
| circRNA15696 | 370 | chr4 | 86678177 | 86680931 | - | 344 | 322 | 46 | 103 | 0 | 1 |
| circRNA9290 | 308 | chr18 | 3265454 | 3267976 | - | 340 | 507 | 20 | 479 | 0 | 1 |
| circRNA6180 | 648 | chr16 | 50273975 | 50284075 | - | 334 | 433 | 35 | 221 | 0 | 3 |
| circRNA19211 | 510 | chr1 | 11958024 | 11987172 | - | 332 | 122 | 19 | 0 | 0 | 0 |
| circRNA8865 | 338 | chr19 | 13158661 | 13159166 | - | 331 | 679 | 33 | 315 | 0 | 1 |
| circRNA1636 | 242 | chr12 | 36504074 | 36507305 | - | 330 | 506 | 70 | 115 | 4 | 21 |
| circRNA15345 | 641 | chr4 | 41020428 | 41024971 | - | 328 | 415 | 11 | 83 | 0 | 0 |
| circRNA3872 | 322 | chr11 | 127899150 | 127902805 | + | 322 | 461 | 61 | 283 | 3 | 2 |
| circRNA10373 | 634 | chr20 | 35176581 | 35224656 | + | 320 | 409 | 13 | 77 | 1 | 0 |
| circRNA11778 | 623 | chr7 | 85078770 | 85079478 | - | 318 | 504 | 15 | 233 | 2 | 1 |
| circRNA10342 | 327 | chr20 | 29885402 | 29885827 | + | 312 | 2190 | 346 | 32 | 352 | 235 |
| circRNA7190 | 395 | chr15 | 59306158 | 59317141 | - | 312 | 409 | 9 | 109 | 4 | 6 |
| circRNA23518 | 492 | chr8 | 106589098 | 106814255 | + | 307 | 257 | 51 | 13 | 2 | 0 |
| circRNA4981 | 328 | chr17 | 6204819 | 6220673 | + | 306 | 445 | 40 | 7 | 2 | 3 |
| circRNA20032 | 459 | chr1 | 85905805 | 85935497 | - | 294 | 443 | 26 | 36 | 2 | 0 |
| circRNA19210 | 293 | chr1 | 11958024 | 11984448 | - | 291 | 315 | 39 | 0 | 0 | 0 |
| circRNA1457 | 320 | chr13 | 102044550 | 102103799 | + | 285 | 98 | 10 | 9 | 0 | 0 |
| circRNA5066 | 438 | chr17 | 12066093 | 12076423 | - | 285 | 118 | 29 | 63 | 0 | 3 |
| circRNA14811 | 413 | chr5 | 147129437 | 147148995 | + | 283 | 752 | 42 | 45 | 0 | 2 |
| circRNA19188 | 1202 | chr1 | 11920919 | 11987172 | - | 282 | 88 | 0 | 0 | 0 | 0 |
document location: summary/3_1_circRNA_candidate_prediction/6_circRNA_backsplice_reads.xlsx
| Accession | EM01_M_count | EM02_M_count | EM03_M_count | KTY01_K_count | KTY02_K_count | KTY03_K_count | EM01_M_fpkm | EM02_M_fpkm | EM03_M_fpkm | KTY01_K_fpkm | KTY02_K_fpkm | KTY03_K_fpkm | mean_fpkm_K | mean_fpkm_M | regulation | log2fold_change | pvalue | FDR | significant | chr | start | end | strand | exon Count | circType | circRNA category | isoformName | geneName | hosting gene type | flankIntron | gene Discription | GO | KEGG |
| circRNA2424 | 11526.83 | 8978 | 9109 | 13 | 23 | 13 | 962.48 | 961.62 | 961.51 | 1.10 | 1.96 | 1.28 | 1.45 | 961.87 | down | -9.38 | 0.00 | 0.00 | yes | chr7 | 99770122 | 99780085 | - | 4 | circRNA | - | ENST00000336411 | CYP3A4 | mRNA | chr7:99769856-99770121|chr7:99780085-99784010 | cytochrome P450, family 3, subfamily A, polypeptide 4 [Source:HGNC Symbol;Acc:HGNC:2637] | GO:0004497(monooxygenase activity);GO:0005496(steroid binding);GO:0005506(iron ion binding);GO:0005737(cytoplasm);GO:0005789(endoplasmic reticulum membrane);GO:0006629(lipid metabolic process);GO:0006706(steroid catabolic process);GO:0006805(xenobiotic metabolic process);GO:0008202(steroid metabolic process);GO:0008209(androgen metabolic process);GO:0008395(steroid hydroxylase activity);GO:0009822(alkaloid catabolic process);GO:0016021(integral component of membrane);GO:0016098(monoterpenoid metabolic process);GO:0016491(oxidoreductase activity);GO:0016705(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen);GO:0016712(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen);GO:0017144(drug metabolic process);GO:0019825(oxygen binding);GO:0019899(enzyme binding);GO:0020037(heme binding);GO:0030343(vitamin D3 25-hydroxylase activity);GO:0033780(taurochenodeoxycholate 6alpha-hydroxylase activity);GO:0034875(caffeine oxidase activity);GO:0036378(calcitriol biosynthetic process from calciol);GO:0042359(vitamin D metabolic process);GO:0042737(drug catabolic process);GO:0042738(exogenous drug catabolic process);GO:0043231(intracellular membrane-bounded organelle);GO:0044281(small molecule metabolic process);GO:0046483(heterocycle metabolic process);GO:0047638(albendazole monooxygenase activity);GO:0050591(quinine 3-monooxygenase activity);GO:0050649(testosterone 6-beta-hydroxylase activity);GO:0055114(oxidation-reduction process);GO:0070576(vitamin D 24-hydroxylase activity);GO:0070989(oxidative demethylation) | NA |
| circRNA403 | 278.50 | 207 | 215 | 0 | 2 | 0 | 20.28 | 19.33 | 19.79 | 0 | 0.15 | 0 | 0.05 | 19.80 | down | -8.65 | 0.00 | 0.00 | yes | chr12 | 103733006 | 103737780 | + | 3 | circRNA | - | ENST00000388887 | STAB2 | mRNA | chr12:103731635-103733005|chr12:103737780-103739411 | stabilin 2 [Source:HGNC Symbol;Acc:HGNC:18629] | GO:0001525(angiogenesis);GO:0005041(low-density lipoprotein receptor activity);GO:0005044(scavenger receptor activity);GO:0005509(calcium ion binding);GO:0005515(protein binding);GO:0005540(hyaluronic acid binding);GO:0005737(cytoplasm);GO:0005886(plasma membrane);GO:0005887(integral component of plasma membrane);GO:0005975(carbohydrate metabolic process);GO:0006897(endocytosis);GO:0006898(receptor-mediated endocytosis);GO:0007155(cell adhesion);GO:0009897(external side of plasma membrane);GO:0010468(regulation of gene expression);GO:0015035(protein disulfide oxidoreductase activity);GO:0030169(low-density lipoprotein particle binding);GO:0030193(regulation of blood coagulation);GO:0030203(glycosaminoglycan metabolic process);GO:0030212(hyaluronan metabolic process);GO:0030214(hyaluronan catabolic process);GO:0030666(endocytic vesicle membrane);GO:0042742(defense response to bacterium);GO:0044281(small molecule metabolic process);GO:0055114(oxidation-reduction process) | NA |
| circRNA3426 | 117 | 88 | 91 | 0.33 | 0.33 | 0.33 | 3.88 | 3.74 | 3.81 | 0.01 | 0.01 | 0.01 | 0.01 | 3.81 | down | -8.33 | 0.00 | 0.00 | yes | chr3 | 74361890 | 74371399 | - | 6 | circRNA | - | ENST00000263665 | CNTN3 | mRNA | chr3:74336658-74361889|chr3:74371399-74424844 | contactin 3 (plasmacytoma associated) [Source:HGNC Symbol;Acc:HGNC:2173] | GO:0005515(protein binding);GO:0005886(plasma membrane);GO:0007155(cell adhesion);GO:0007399(nervous system development);GO:0031225(anchored component of membrane) | NA |
| circRNA939 | 1459.14 | 1136.94 | 1153.35 | 2.47 | 9.37 | 2.07 | 90.13 | 90.08 | 90.06 | 0.15 | 0.59 | 0.15 | 0.30 | 90.09 | down | -8.24 | 0.00 | 0.00 | yes | chr10 | 95058335 | 95067357 | - | 3 | circRNA | - | ENST00000535898 | CYP2C8 | mRNA | chr10:95045951-95058334|chr10:95067357-95069196 | cytochrome P450, family 2, subfamily C, polypeptide 8 [Source:HGNC Symbol;Acc:HGNC:2622] | GO:0004497(monooxygenase activity);GO:0005506(iron ion binding);GO:0005737(cytoplasm);GO:0005789(endoplasmic reticulum membrane);GO:0006082(organic acid metabolic process);GO:0006805(xenobiotic metabolic process);GO:0008392(arachidonic acid epoxygenase activity);GO:0008395(steroid hydroxylase activity);GO:0016705(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen);GO:0016712(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen);GO:0017144(drug metabolic process);GO:0019369(arachidonic acid metabolic process);GO:0019373(epoxygenase P450 pathway);GO:0019825(oxygen binding);GO:0020037(heme binding);GO:0034875(caffeine oxidase activity);GO:0042738(exogenous drug catabolic process);GO:0043231(intracellular membrane-bounded organelle);GO:0044281(small molecule metabolic process);GO:0055114(oxidation-reduction process);GO:0070330(aromatase activity);GO:0070989(oxidative demethylation);GO:0097267(omega-hydroxylase P450 pathway) | 00590(Arachidonic acid metabolism);00591(Linoleic acid metabolism);00830(Retinol metabolism);00980(Metabolism of xenobiotics by cytochrome P450);00982(Drug metabolism - cytochrome P450);01100(Metabolic pathways) |
| circRNA1757 | 204.67 | 157.33 | 160.33 | 0.67 | 0.67 | 0.67 | 34.47 | 33.99 | 34.13 | 0.11 | 0.11 | 0.13 | 0.12 | 34.19 | down | -8.15 | 0.00 | 0.00 | yes | chr14 | 69779182 | 69779360 | - | 1 | circRNA | - | ENST00000216540 | SLC10A1 | mRNA | chr14:69778529-69779181|chr14:69779360-69786096 | solute carrier family 10 (sodium/bile acid cotransporter), member 1 [Source:HGNC Symbol;Acc:HGNC:10905] | GO:0005886(plasma membrane);GO:0005887(integral component of plasma membrane);GO:0006810(transport);GO:0006814(sodium ion transport);GO:0008206(bile acid metabolic process);GO:0008508(bile acid:sodium symporter activity);GO:0015125(bile acid transmembrane transporter activity);GO:0015721(bile acid and bile salt transport);GO:0016020(membrane);GO:0016323(basolateral plasma membrane);GO:0044281(small molecule metabolic process);GO:0055085(transmembrane transport) | NA |
| circRNA4751 | 89 | 71 | 72 | 1 | 0 | 0 | 9.94 | 10.17 | 10.16 | 0.11 | 0 | 0 | 0.04 | 10.09 | down | -8.07 | 0.00 | 0.00 | yes | chr9 | 133437749 | 133438366 | + | 2 | circRNA | - | ENST00000371929 | ADAMTS13 | mRNA | chr9:133436955-133437748|chr9:133438366-133439365 | NA | GO:0004222(metalloendopeptidase activity);GO:0006508(proteolysis) | NA |
| circRNA2329 | 1143 | 871 | 890 | 4 | 4 | 4 | 29.47 | 28.81 | 29.01 | 0.10 | 0.11 | 0.12 | 0.11 | 29.10 | down | -8.04 | 0.00 | 0.00 | yes | chr7 | 34046306 | 34086092 | + | 7 | circRNA | - | ENST00000297161 | BMPER | mRNA | chr7:33974784-34046305|chr7:34086092-34143229 | BMP binding endothelial regulator [Source:HGNC Symbol;Acc:HGNC:24154] | GO:0001657(ureteric bud development);GO:0002043(blood vessel endothelial cell proliferation involved in sprouting angiogenesis);GO:0005515(protein binding);GO:0005576(extracellular region);GO:0005615(extracellular space);GO:0010594(regulation of endothelial cell migration);GO:0030514(negative regulation of BMP signaling pathway);GO:0042118(endothelial cell activation);GO:0045446(endothelial cell differentiation);GO:0048839(inner ear development);GO:0060393(regulation of pathway-restricted SMAD protein phosphorylation);GO:0070374(positive regulation of ERK1 and ERK2 cascade) | NA |
| circRNA940 | 1946.39 | 1521.37 | 1542.03 | 3.72 | 15.12 | 3.07 | 90.12 | 90.36 | 90.26 | 0.17 | 0.71 | 0.17 | 0.35 | 90.25 | down | -8.00 | 0.00 | 0.00 | yes | chr10 | 95058335 | 95067691 | - | 4 | circRNA | - | ENST00000539050 | CYP2C8 | mRNA | chr10:95045951-95058334|chr10:95067691-95068566 | cytochrome P450, family 2, subfamily C, polypeptide 8 [Source:HGNC Symbol;Acc:HGNC:2622] | GO:0004497(monooxygenase activity);GO:0005506(iron ion binding);GO:0005737(cytoplasm);GO:0005789(endoplasmic reticulum membrane);GO:0006082(organic acid metabolic process);GO:0006805(xenobiotic metabolic process);GO:0008392(arachidonic acid epoxygenase activity);GO:0008395(steroid hydroxylase activity);GO:0016705(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen);GO:0016712(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen);GO:0017144(drug metabolic process);GO:0019369(arachidonic acid metabolic process);GO:0019373(epoxygenase P450 pathway);GO:0019825(oxygen binding);GO:0020037(heme binding);GO:0034875(caffeine oxidase activity);GO:0042738(exogenous drug catabolic process);GO:0043231(intracellular membrane-bounded organelle);GO:0044281(small molecule metabolic process);GO:0055114(oxidation-reduction process);GO:0070330(aromatase activity);GO:0070989(oxidative demethylation);GO:0097267(omega-hydroxylase P450 pathway) | 00590(Arachidonic acid metabolism);00591(Linoleic acid metabolism);00830(Retinol metabolism);00980(Metabolism of xenobiotics by cytochrome P450);00982(Drug metabolism - cytochrome P450);01100(Metabolic pathways) |
| circRNA938 | 4098.05 | 3219.20 | 3266.86 | 8.22 | 32.62 | 6.07 | 155.77 | 156.97 | 156.98 | 0.32 | 1.26 | 0.27 | 0.62 | 156.57 | down | -7.99 | 0.00 | 0.00 | yes | chr10 | 95045810 | 95067691 | - | 5 | circRNA | - | ENST00000539050 | CYP2C8 | mRNA | chr10:95043077-95045809|chr10:95067691-95068566 | cytochrome P450, family 2, subfamily C, polypeptide 8 [Source:HGNC Symbol;Acc:HGNC:2622] | GO:0004497(monooxygenase activity);GO:0005506(iron ion binding);GO:0005737(cytoplasm);GO:0005789(endoplasmic reticulum membrane);GO:0006082(organic acid metabolic process);GO:0006805(xenobiotic metabolic process);GO:0008392(arachidonic acid epoxygenase activity);GO:0008395(steroid hydroxylase activity);GO:0016705(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen);GO:0016712(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen);GO:0017144(drug metabolic process);GO:0019369(arachidonic acid metabolic process);GO:0019373(epoxygenase P450 pathway);GO:0019825(oxygen binding);GO:0020037(heme binding);GO:0034875(caffeine oxidase activity);GO:0042738(exogenous drug catabolic process);GO:0043231(intracellular membrane-bounded organelle);GO:0044281(small molecule metabolic process);GO:0055114(oxidation-reduction process);GO:0070330(aromatase activity);GO:0070989(oxidative demethylation);GO:0097267(omega-hydroxylase P450 pathway) | 00590(Arachidonic acid metabolism);00591(Linoleic acid metabolism);00830(Retinol metabolism);00980(Metabolism of xenobiotics by cytochrome P450);00982(Drug metabolism - cytochrome P450);01100(Metabolic pathways) |
| circRNA937 | 7966.81 | 6264.32 | 6353.97 | 15.22 | 63.62 | 13.07 | 244.80 | 246.91 | 246.81 | 0.47 | 1.99 | 0.47 | 0.98 | 246.17 | down | -7.97 | 0.00 | 0.00 | yes | chr10 | 95042890 | 95067691 | - | 6 | circRNA | - | ENST00000539050 | CYP2C8 | mRNA | chr10:95039038-95042889|chr10:95067691-95068566 | cytochrome P450, family 2, subfamily C, polypeptide 8 [Source:HGNC Symbol;Acc:HGNC:2622] | GO:0004497(monooxygenase activity);GO:0005506(iron ion binding);GO:0005737(cytoplasm);GO:0005789(endoplasmic reticulum membrane);GO:0006082(organic acid metabolic process);GO:0006805(xenobiotic metabolic process);GO:0008392(arachidonic acid epoxygenase activity);GO:0008395(steroid hydroxylase activity);GO:0016705(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen);GO:0016712(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen);GO:0017144(drug metabolic process);GO:0019369(arachidonic acid metabolic process);GO:0019373(epoxygenase P450 pathway);GO:0019825(oxygen binding);GO:0020037(heme binding);GO:0034875(caffeine oxidase activity);GO:0042738(exogenous drug catabolic process);GO:0043231(intracellular membrane-bounded organelle);GO:0044281(small molecule metabolic process);GO:0055114(oxidation-reduction process);GO:0070330(aromatase activity);GO:0070989(oxidative demethylation);GO:0097267(omega-hydroxylase P450 pathway) | 00590(Arachidonic acid metabolism);00591(Linoleic acid metabolism);00830(Retinol metabolism);00980(Metabolism of xenobiotics by cytochrome P450);00982(Drug metabolism - cytochrome P450);01100(Metabolic pathways) |
| circRNA941 | 1395.24 | 1089.73 | 1104.64 | 3.72 | 12.62 | 3.07 | 88.73 | 88.89 | 88.80 | 0.24 | 0.82 | 0.23 | 0.43 | 88.81 | down | -7.69 | 0.00 | 0.00 | yes | chr10 | 95064800 | 95067691 | - | 3 | circRNA | - | ENST00000539050 | CYP2C8 | mRNA | chr10:95058511-95064799|chr10:95067691-95068566 | cytochrome P450, family 2, subfamily C, polypeptide 8 [Source:HGNC Symbol;Acc:HGNC:2622] | GO:0004497(monooxygenase activity);GO:0005506(iron ion binding);GO:0005737(cytoplasm);GO:0005789(endoplasmic reticulum membrane);GO:0006082(organic acid metabolic process);GO:0006805(xenobiotic metabolic process);GO:0008392(arachidonic acid epoxygenase activity);GO:0008395(steroid hydroxylase activity);GO:0016705(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen);GO:0016712(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen);GO:0017144(drug metabolic process);GO:0019369(arachidonic acid metabolic process);GO:0019373(epoxygenase P450 pathway);GO:0019825(oxygen binding);GO:0020037(heme binding);GO:0034875(caffeine oxidase activity);GO:0042738(exogenous drug catabolic process);GO:0043231(intracellular membrane-bounded organelle);GO:0044281(small molecule metabolic process);GO:0055114(oxidation-reduction process);GO:0070330(aromatase activity);GO:0070989(oxidative demethylation);GO:0097267(omega-hydroxylase P450 pathway) | 00590(Arachidonic acid metabolism);00591(Linoleic acid metabolism);00830(Retinol metabolism);00980(Metabolism of xenobiotics by cytochrome P450);00982(Drug metabolism - cytochrome P450);01100(Metabolic pathways) |
| circRNA6111 | 1 | 0 | 0 | 281 | 287 | 239 | 0.09 | 0 | 0 | 26.22 | 26.93 | 26.05 | 26.40 | 0.03 | up | 9.75 | 0.00 | 0.00 | yes | chr17 | 40406384 | 40406942 | - | 3 | circRNA | - | ENST00000423485 | TOP2A | mRNA | chr17:40404883-40406383|chr17:40406942-40407548 | topoisomerase (DNA) II alpha 170kDa [Source:HGNC Symbol;Acc:HGNC:11989] | GO:0000228(nuclear chromosome);GO:0000278(mitotic cell cycle);GO:0000287(magnesium ion binding);GO:0000712(resolution of meiotic recombination intermediates);GO:0000793(condensed chromosome);GO:0000819(sister chromatid segregation);GO:0002244(hematopoietic progenitor cell differentiation);GO:0003677(DNA binding);GO:0003682(chromatin binding);GO:0003918(DNA topoisomerase type II (ATP-hydrolyzing) activity);GO:0005080(protein kinase C binding);GO:0005515(protein binding);GO:0005524(ATP binding);GO:0005634(nucleus);GO:0005654(nucleoplasm);GO:0005730(nucleolus);GO:0005814(centriole);GO:0006265(DNA topological change);GO:0006266(DNA ligation);GO:0006268(DNA unwinding involved in DNA replication);GO:0006974(cellular response to DNA damage stimulus);GO:0007059(chromosome segregation);GO:0008022(protein C-terminus binding);GO:0008094(DNA-dependent ATPase activity);GO:0008144(drug binding);GO:0008301(DNA binding, bending);GO:0009330(DNA topoisomerase complex (ATP-hydrolyzing));GO:0019035(viral integration complex);GO:0019899(enzyme binding);GO:0030261(chromosome condensation);GO:0030263(apoptotic chromosome condensation);GO:0040016(embryonic cleavage);GO:0042752(regulation of circadian rhythm);GO:0042803(protein homodimerization activity);GO:0042826(histone deacetylase binding);GO:0043065(positive regulation of apoptotic process);GO:0043130(ubiquitin binding);GO:0043234(protein complex);GO:0044774(mitotic DNA integrity checkpoint);GO:0044822(poly(A) RNA binding);GO:0045070(positive regulation of viral genome replication);GO:0045870(positive regulation of single stranded viral RNA replication via double stranded DNA intermediate);GO:0045944(positive regulation of transcription from RNA polymerase II promoter);GO:0046982(protein heterodimerization activity);GO:0048511(rhythmic process) | NA |
| circRNA5162 | 2.50 | 1.50 | 1.50 | 1725.92 | 1330.25 | 1472.25 | 0.17 | 0.13 | 0.13 | 119.97 | 92.99 | 119.54 | 110.83 | 0.14 | up | 9.58 | 0.01 | 0.01 | yes | chr13 | 63990096 | 64034537 | - | 4 | circRNA | lincRNA | ENST00000456627 | LINC00355 | lncRNA | chr13:63987039-63990095|chr13:64034537-64075241 | NA | NA | NA |
| circRNA5163 | 1.50 | 1.50 | 1.50 | 892.92 | 691.25 | 767.25 | 0.14 | 0.17 | 0.17 | 81.58 | 63.51 | 81.88 | 75.66 | 0.16 | up | 8.88 | 0.01 | 0.01 | yes | chr13 | 64002385 | 64034537 | - | 3 | circRNA | lincRNA | ENST00000456627 | LINC00355 | lncRNA | chr13:63990200-64002384|chr13:64034537-64075241 | NA | NA | NA |
| circRNA6394 | 1 | 0 | 0 | 172.25 | 127.25 | 135.25 | 0.09 | 0 | 0 | 15.37 | 11.42 | 14.10 | 13.63 | 0.03 | up | 8.86 | 0.01 | 0.01 | yes | chr16 | 29895259 | 29895860 | - | 2 | circRNA | - | ENST00000350527 | SEZ6L2 | mRNA | chr16:29888725-29895258|chr16:29895860-29896821 | seizure related 6 homolog (mouse)-like 2 [Source:HGNC Symbol;Acc:HGNC:30844] | GO:0005783(endoplasmic reticulum);GO:0005789(endoplasmic reticulum membrane);GO:0005886(plasma membrane);GO:0008344(adult locomotory behavior);GO:0016021(integral component of membrane);GO:0021680(cerebellar Purkinje cell layer development);GO:0043025(neuronal cell body);GO:0060074(synapse maturation);GO:0090036(regulation of protein kinase C signaling) | NA |
| circRNA6376 | 1 | 1 | 1 | 547.93 | 437.14 | 468.64 | 0.02 | 0.02 | 0.02 | 9.00 | 7.22 | 9.00 | 8.41 | 0.02 | up | 8.78 | 0.00 | 0.01 | yes | chr16 | 20969792 | 20988065 | - | 8 | circRNA | - | ENST00000261383 | DNAH3 | mRNA | chr16:20965425-20969791|chr16:20988065-20997282 | dynein, axonemal, heavy chain 3 [Source:HGNC Symbol;Acc:HGNC:2949] | GO:0001539(cilium or flagellum-dependent cell motility);GO:0003777(microtubule motor activity);GO:0005524(ATP binding);GO:0005858(axonemal dynein complex);GO:0005874(microtubule);GO:0007018(microtubule-based movement);GO:0008152(metabolic process);GO:0030286(dynein complex) | 05016(Huntington's disease) |
| circRNA9214 | 1 | 0 | 0 | 135 | 146 | 113 | 0.07 | 0 | 0 | 10.02 | 10.90 | 9.80 | 10.24 | 0.02 | up | 8.71 | 0.00 | 0.00 | yes | chr1 | 214614832 | 214619220 | + | 3 | circRNA | - | ENST00000366955 | CENPF | mRNA | chr1:214613916-214614831|chr1:214619220-214620654 | centromere protein F, 350/400kDa [Source:HGNC Symbol;Acc:HGNC:1857] | GO:0000086(G2/M transition of mitotic cell cycle);GO:0000278(mitotic cell cycle);GO:0000775(chromosome, centromeric region);GO:0000776(kinetochore);GO:0000785(chromatin);GO:0000922(spindle pole);GO:0000940(condensed chromosome outer kinetochore);GO:0003682(chromatin binding);GO:0005515(protein binding);GO:0005634(nucleus);GO:0005635(nuclear envelope);GO:0005654(nucleoplasm);GO:0005737(cytoplasm);GO:0005819(spindle);GO:0005829(cytosol);GO:0007059(chromosome segregation);GO:0007067(mitotic nuclear division);GO:0007094(mitotic spindle assembly checkpoint);GO:0007264(small GTPase mediated signal transduction);GO:0007517(muscle organ development);GO:0008022(protein C-terminus binding);GO:0008134(transcription factor binding);GO:0008283(cell proliferation);GO:0010389(regulation of G2/M transition of mitotic cell cycle);GO:0015031(protein transport);GO:0016202(regulation of striated muscle tissue development);GO:0016363(nuclear matrix);GO:0030154(cell differentiation);GO:0030496(midbody);GO:0042493(response to drug);GO:0042803(protein homodimerization activity);GO:0045120(pronucleus);GO:0045502(dynein binding);GO:0045892(negative regulation of transcription, DNA-templated);GO:0048471(perinuclear region of cytoplasm);GO:0051301(cell division);GO:0051310(metaphase plate congression);GO:0051382(kinetochore assembly);GO:0051726(regulation of cell cycle);GO:0071897(DNA biosynthetic process) | NA |
| circRNA5418 | 3 | 3 | 3 | 1431.50 | 1134.50 | 1245.50 | 0.08 | 0.10 | 0.10 | 36.77 | 29.30 | 37.37 | 34.48 | 0.09 | up | 8.58 | 0.01 | 0.01 | yes | chr12 | 97492461 | 97561047 | + | 7 | circRNA | processed_transcript | ENST00000538559 | RMST | lncRNA | chr12:97463289-97492460|chr12:97561047-97564149 | NA | NA | NA |
| circRNA6058 | 11 | 8 | 8 | 3144.50 | 2442.50 | 2700.50 | 0.41 | 0.38 | 0.38 | 118.17 | 92.31 | 118.55 | 109.67 | 0.39 | up | 8.14 | 0.01 | 0.01 | yes | chr17 | 19741093 | 19745134 | - | 5 | circRNA | - | ENST00000395555 | ALDH3A1 | mRNA | chr17:19739624-19741092|chr17:19745134-19748258 | aldehyde dehydrogenase 3 family, member A1 [Source:HGNC Symbol;Acc:HGNC:405] | GO:0001666(response to hypoxia);GO:0004028(3-chloroallyl aldehyde dehydrogenase activity);GO:0004029(aldehyde dehydrogenase (NAD) activity);GO:0004030(aldehyde dehydrogenase [NAD(P)+] activity);GO:0005615(extracellular space);GO:0005654(nucleoplasm);GO:0005737(cytoplasm);GO:0005783(endoplasmic reticulum);GO:0005829(cytosol);GO:0005886(plasma membrane);GO:0006081(cellular aldehyde metabolic process);GO:0007568(aging);GO:0007584(response to nutrient);GO:0008106(alcohol dehydrogenase (NADP+) activity);GO:0008152(metabolic process);GO:0008284(positive regulation of cell proliferation);GO:0014070(response to organic cyclic compound);GO:0016491(oxidoreductase activity);GO:0016620(oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor);GO:0018479(benzaldehyde dehydrogenase (NAD+) activity);GO:0042493(response to drug);GO:0043231(intracellular membrane-bounded organelle);GO:0051384(response to glucocorticoid);GO:0051591(response to cAMP);GO:0055114(oxidation-reduction process) | 00010(Glycolysis / Gluconeogenesis);00340(Histidine metabolism);00350(Tyrosine metabolism);00360(Phenylalanine metabolism);00410(beta-Alanine metabolism);00980(Metabolism of xenobiotics by cytochrome P450);00982(Drug metabolism - cytochrome P450);01100(Metabolic pathways) |
| circRNA7262 | 5.50 | 5.50 | 5.50 | 1418 | 1322 | 1220 | 0.24 | 0.30 | 0.30 | 61.37 | 57.54 | 61.68 | 60.20 | 0.28 | up | 7.76 | 0.00 | 0.00 | yes | chr7 | 23345940 | 23418824 | - | 6 | circRNA | - | ENST00000258729 | IGF2BP3 | mRNA | chr7:23343853-23345939|chr7:23418824-23468481 | insulin-like growth factor 2 mRNA binding protein 3 [Source:HGNC Symbol;Acc:HGNC:28868] | GO:0000166(nucleotide binding);GO:0003676(nucleic acid binding);GO:0003723(RNA binding);GO:0003730(mRNA 3'-UTR binding);GO:0005515(protein binding);GO:0005634(nucleus);GO:0005737(cytoplasm);GO:0005829(cytosol);GO:0006412(translation);GO:0009653(anatomical structure morphogenesis);GO:0010467(gene expression);GO:0017148(negative regulation of translation);GO:0042035(regulation of cytokine biosynthetic process);GO:0044822(poly(A) RNA binding);GO:0045182(translation regulator activity);GO:0048027(mRNA 5'-UTR binding);GO:0051028(mRNA transport) | NA |
| circRNA5971 | 9 | 7 | 7 | 1600 | 1245 | 1358.50 | 0.59 | 0.59 | 0.58 | 107.07 | 83.78 | 106.19 | 99.01 | 0.59 | up | 7.39 | 0.01 | 0.01 | yes | chr10 | 102834036 | 102835392 | - | 3 | circRNA | - | ENST00000369887 | CYP17A1 | mRNA | chr10:102833208-102834035|chr10:102835392-102837064 | cytochrome P450, family 17, subfamily A, polypeptide 1 [Source:HGNC Symbol;Acc:HGNC:2593] | GO:0004508(steroid 17-alpha-monooxygenase activity);GO:0005506(iron ion binding);GO:0005739(mitochondrion);GO:0005783(endoplasmic reticulum);GO:0005789(endoplasmic reticulum membrane);GO:0006694(steroid biosynthetic process);GO:0006702(androgen biosynthetic process);GO:0006704(glucocorticoid biosynthetic process);GO:0006805(xenobiotic metabolic process);GO:0007548(sex differentiation);GO:0008202(steroid metabolic process);GO:0016125(sterol metabolic process);GO:0016705(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen);GO:0019825(oxygen binding);GO:0020037(heme binding);GO:0030424(axon);GO:0042446(hormone biosynthetic process);GO:0042448(progesterone metabolic process);GO:0043025(neuronal cell body);GO:0044281(small molecule metabolic process);GO:0047442(17-alpha-hydroxyprogesterone aldolase activity);GO:0055114(oxidation-reduction process) | 00140(Steroid hormone biosynthesis);01100(Metabolic pathways) |
| circRNA5063 | 43 | 35 | 37 | 7992.43 | 6232.23 | 6825.23 | 1.51 | 1.58 | 1.65 | 284.58 | 223.16 | 283.88 | 263.87 | 1.58 | up | 7.38 | 0.01 | 0.01 | yes | chrX | 111123077 | 111173081 | + | 7 | circRNA | - | ENST00000425146 | PAK3 | mRNA | chrX:110944628-111123076|chrX:111173081-111192126 | p21 protein (Cdc42/Rac)-activated kinase 3 [Source:HGNC Symbol;Acc:HGNC:8592] | GO:0000165(MAPK cascade);GO:0000187(activation of MAPK activity);GO:0002223(stimulatory C-type lectin receptor signaling pathway);GO:0004672(protein kinase activity);GO:0004674(protein serine/threonine kinase activity);GO:0004708(MAP kinase kinase activity);GO:0005515(protein binding);GO:0005524(ATP binding);GO:0005737(cytoplasm);GO:0005768(endosome);GO:0005829(cytosol);GO:0005886(plasma membrane);GO:0006468(protein phosphorylation);GO:0007264(small GTPase mediated signal transduction);GO:0007266(Rho protein signal transduction);GO:0007346(regulation of mitotic cell cycle);GO:0007409(axonogenesis);GO:0007411(axon guidance);GO:0010975(regulation of neuron projection development);GO:0016358(dendrite development);GO:0016477(cell migration);GO:0016772(transferase activity, transferring phosphorus-containing groups);GO:0017048(Rho GTPase binding);GO:0017124(SH3 domain binding);GO:0030036(actin cytoskeleton organization);GO:0030833(regulation of actin filament polymerization);GO:0031098(stress-activated protein kinase signaling cascade);GO:0031295(T cell costimulation);GO:0042981(regulation of apoptotic process);GO:0043525(positive regulation of neuron apoptotic process);GO:0045087(innate immune response);GO:0046872(metal ion binding);GO:0048010(vascular endothelial growth factor receptor signaling pathway);GO:0048013(ephrin receptor signaling pathway);GO:0048365(Rac GTPase binding);GO:0050808(synapse organization);GO:0050852(T cell receptor signaling pathway);GO:0051020(GTPase binding);GO:0060996(dendritic spine development);GO:0060997(dendritic spine morphogenesis);GO:0061003(positive regulation of dendritic spine morphogenesis);GO:0071407(cellular response to organic cyclic compound);GO:2000573(positive regulation of DNA biosynthetic process) | 04012(ErbB signaling pathway);04360(Axon guidance);04510(Focal adhesion);04660(T cell receptor signaling pathway);04810(Regulation of actin cytoskeleton);05211(Renal cell carcinoma) |
| circRNA9191 | 1 | 1 | 1 | 174 | 153 | 151 | 0.03 | 0.04 | 0.04 | 5.84 | 5.17 | 5.92 | 5.64 | 0.04 | up | 7.17 | 0.00 | 0.01 | yes | chr1 | 200600050 | 200608928 | - | 9 | circRNA | - | ENST00000614960 | KIF14 | mRNA | chr1:200598421-200600049|chr1:200608928-200614317 | kinesin family member 14 [Source:HGNC Symbol;Acc:HGNC:19181] | GO:0001558(regulation of cell growth);GO:0003777(microtubule motor activity);GO:0005515(protein binding);GO:0005524(ATP binding);GO:0005634(nucleus);GO:0005829(cytosol);GO:0005871(kinesin complex);GO:0005874(microtubule);GO:0005886(plasma membrane);GO:0007018(microtubule-based movement);GO:0007080(mitotic metaphase plate congression);GO:0007264(small GTPase mediated signal transduction);GO:0008017(microtubule binding);GO:0008284(positive regulation of cell proliferation);GO:0008574(ATP-dependent microtubule motor activity, plus-end-directed);GO:0010389(regulation of G2/M transition of mitotic cell cycle);GO:0015631(tubulin binding);GO:0016020(membrane);GO:0016887(ATPase activity);GO:0019901(protein kinase binding);GO:0021685(cerebellar granular layer structural organization);GO:0021693(cerebellar Purkinje cell layer structural organization);GO:0021695(cerebellar cortex development);GO:0021766(hippocampus development);GO:0021772(olfactory bulb development);GO:0021846(cell proliferation in forebrain);GO:0021987(cerebral cortex development);GO:0030155(regulation of cell adhesion);GO:0030165(PDZ domain binding);GO:0030334(regulation of cell migration);GO:0030496(midbody);GO:0030705(cytoskeleton-dependent intracellular transport);GO:0031146(SCF-dependent proteasomal ubiquitin-dependent protein catabolic process);GO:0031641(regulation of myelination);GO:0032147(activation of protein kinase activity);GO:0032467(positive regulation of cytokinesis);GO:0032487(regulation of Rap protein signal transduction);GO:0033624(negative regulation of integrin activation);GO:0034446(substrate adhesion-dependent cell spreading);GO:0043066(negative regulation of apoptotic process);GO:0043161(proteasome-mediated ubiquitin-dependent protein catabolic process);GO:0043523(regulation of neuron apoptotic process);GO:0043524(negative regulation of neuron apoptotic process);GO:0045184(establishment of protein localization);GO:0051233(spindle midzone);GO:0051301(cell division);GO:1903047(mitotic cell cycle process);GO:1903429(regulation of cell maturation);GO:2000045(regulation of G1/S transition of mitotic cell cycle) | NA |
| circRNA6675 | 1 | 1 | 1 | 167 | 132 | 142 | 0.05 | 0.06 | 0.06 | 7.90 | 6.28 | 7.85 | 7.34 | 0.06 | up | 7.05 | 0.01 | 0.01 | yes | chr14 | 46855024 | 46882221 | - | 5 | circRNA | - | ENST00000426342 | MDGA2 | mRNA | chr14:46845871-46855023|chr14:46882221-46920011 | MAM domain containing glycosylphosphatidylinositol anchor 2 [Source:HGNC Symbol;Acc:HGNC:19835] | GO:0005515(protein binding);GO:0005886(plasma membrane);GO:0007389(pattern specification process);GO:0016020(membrane);GO:0021522(spinal cord motor neuron differentiation);GO:0031225(anchored component of membrane) | NA |
| circRNA7001 | 1 | 1 | 1 | 161 | 129 | 137 | 0.08 | 0.10 | 0.10 | 12.69 | 10.23 | 12.62 | 11.85 | 0.09 | up | 7.01 | 0.00 | 0.01 | yes | chr22 | 15698662 | 15708090 | + | 4 | circRNA | - | ENST00000343518 | POTEH | mRNA | chr22:15695818-15698661|chr22:15708090-15709781 | POTE ankyrin domain family, member H [Source:HGNC Symbol;Acc:HGNC:133] | GO:0005515(protein binding) | NA |
| circRNA5970 | 32 | 26 | 26 | 4117.33 | 3232.33 | 3511.83 | 1.20 | 1.25 | 1.23 | 155.68 | 122.91 | 155.12 | 144.57 | 1.22 | up | 6.89 | 0.01 | 0.01 | yes | chr10 | 102831508 | 102835014 | - | 5 | circRNA | - | ENST00000369887 | CYP17A1 | mRNA | chr10:102830985-102831507|chr10:102835014-102835253 | cytochrome P450, family 17, subfamily A, polypeptide 1 [Source:HGNC Symbol;Acc:HGNC:2593] | GO:0004508(steroid 17-alpha-monooxygenase activity);GO:0005506(iron ion binding);GO:0005739(mitochondrion);GO:0005783(endoplasmic reticulum);GO:0005789(endoplasmic reticulum membrane);GO:0006694(steroid biosynthetic process);GO:0006702(androgen biosynthetic process);GO:0006704(glucocorticoid biosynthetic process);GO:0006805(xenobiotic metabolic process);GO:0007548(sex differentiation);GO:0008202(steroid metabolic process);GO:0016125(sterol metabolic process);GO:0016705(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen);GO:0019825(oxygen binding);GO:0020037(heme binding);GO:0030424(axon);GO:0042446(hormone biosynthetic process);GO:0042448(progesterone metabolic process);GO:0043025(neuronal cell body);GO:0044281(small molecule metabolic process);GO:0047442(17-alpha-hydroxyprogesterone aldolase activity);GO:0055114(oxidation-reduction process) | 00140(Steroid hormone biosynthesis);01100(Metabolic pathways) |
| circRNA7284 | 5 | 2 | 2 | 352.50 | 378.50 | 315.50 | 0.16 | 0.08 | 0.08 | 11.70 | 12.64 | 12.24 | 12.19 | 0.11 | up | 6.79 | 0.00 | 0.00 | yes | chr7 | 36410514 | 36420314 | + | 6 | circRNA | - | ENST00000265748 | ANLN | mRNA | chr7:36407956-36410513|chr7:36420314-36420596 | anillin, actin binding protein [Source:HGNC Symbol;Acc:HGNC:14082] | GO:0000281(mitotic cytokinesis);GO:0000921(septin ring assembly);GO:0002244(hematopoietic progenitor cell differentiation);GO:0003779(actin binding);GO:0005515(protein binding);GO:0005654(nucleoplasm);GO:0005826(actomyosin contractile ring);GO:0007067(mitotic nuclear division);GO:0007096(regulation of exit from mitosis);GO:0015629(actin cytoskeleton);GO:0043231(intracellular membrane-bounded organelle);GO:0090521(glomerular visceral epithelial cell migration) | NA |
| circRNA6871 | 13 | 12 | 12 | 1563 | 1223 | 1339 | 0.55 | 0.65 | 0.64 | 66.61 | 52.42 | 66.66 | 61.90 | 0.61 | up | 6.66 | 0.01 | 0.01 | yes | chr18 | 10468469 | 10472061 | + | 2 | circRNA | - | ENST00000355285 | APCDD1 | mRNA | chr18:10455039-10468468|chr18:10472061-10485461 | adenomatosis polyposis coli down-regulated 1 [Source:HGNC Symbol;Acc:HGNC:15718] | GO:0001942(hair follicle development);GO:0005887(integral component of plasma membrane);GO:0016055(Wnt signaling pathway);GO:0017147(Wnt-protein binding);GO:0030178(negative regulation of Wnt signaling pathway);GO:0043615(astrocyte cell migration) | NA |
| circRNA5113 | 3 | 1.50 | 1.50 | 240.33 | 192.83 | 202.33 | 0.23 | 0.15 | 0.15 | 18.66 | 15.06 | 18.35 | 17.36 | 0.17 | up | 6.64 | 0.00 | 0.01 | yes | chr13 | 23590150 | 23616045 | + | 3 | circRNA | - | ENST00000248484 | TNFRSF19 | mRNA | chr13:23570848-23590149|chr13:23616045-23626706 | tumor necrosis factor receptor superfamily, member 19 [Source:HGNC Symbol;Acc:HGNC:11915] | GO:0001942(hair follicle development);GO:0005031(tumor necrosis factor-activated receptor activity);GO:0005515(protein binding);GO:0005622(intracellular);GO:0006915(apoptotic process);GO:0007254(JNK cascade);GO:0016021(integral component of membrane);GO:0033209(tumor necrosis factor-mediated signaling pathway);GO:0043123(positive regulation of I-kappaB kinase/NF-kappaB signaling) | 04060(Cytokine-cytokine receptor interaction) |
| circRNA5192 | 61.25 | 40.92 | 41.92 | 5508.42 | 4460.92 | 4695.00 | 1.72 | 1.47 | 1.48 | 156.21 | 127.22 | 155.53 | 146.32 | 1.56 | up | 6.55 | 0.00 | 0.01 | yes | chr13 | 91693187 | 91908057 | + | 4 | circRNA | - | ENST00000377067 | GPC5 | mRNA | chr13:91448922-91693186|chr13:91908057-92144829 | glypican 5 [Source:HGNC Symbol;Acc:HGNC:4453] | GO:0001523(retinoid metabolic process);GO:0005576(extracellular region);GO:0005578(proteinaceous extracellular matrix);GO:0005615(extracellular space);GO:0005796(Golgi lumen);GO:0005886(plasma membrane);GO:0005887(integral component of plasma membrane);GO:0005975(carbohydrate metabolic process);GO:0006024(glycosaminoglycan biosynthetic process);GO:0006027(glycosaminoglycan catabolic process);GO:0007603(phototransduction, visible light);GO:0016020(membrane);GO:0030203(glycosaminoglycan metabolic process);GO:0030204(chondroitin sulfate metabolic process);GO:0031225(anchored component of membrane);GO:0043202(lysosomal lumen);GO:0043395(heparan sulfate proteoglycan binding);GO:0044281(small molecule metabolic process) | NA |
document location: summary/3_2_circRNA_differential_expression/*VS*/1_*VS*_circRNA_differential_expression.xlsx
document location: summary/3_2_circRNA_differential_expression/*VS*/2_*VS*_Volcano.pdf
Heatmap is a graphical representation of data where the individual z values (repeated) or Log10 (non-repeated) contained in a matrix are represented as color scheme. Calculation formula of z value is shown below. Sample-i means expression level (fpkm value).
document location: summary/3_2_circRNA_differential_expression/*VS*/3_*VS*_Heatmap.pdf
Gene ontology (GO) (http://www.geneontology.org) is a major bioinformatics initiative to unify the representation of gene and gene product attributes across all species. More specifically, the project aims to: 1) maintain and develop its controlled vocabulary of gene and gene product attributes; 2) annotate genes and gene products, and assimilate and disseminate annotation data; and 3) provide tools for easy access to all aspects of the data provided by the project, and to enable functional interpretation of experimental data using the GO, for example via enrichment analysis.
GO is part of a larger classification effort, the Open Biomedical Ontologies (OBO).
Although gene nomenclature itself aims to maintain and develop controlled vocabulary of gene and gene products, the Gene Ontology extends the effort by using markup language to make the data (not only of the genes and their products but also of all their attributes) machine readable, and to do so in a way that is unified across all species (whereas gene nomenclature conventions vary by biologic taxon).
Significant GO terms were calculated by Hypergeometric equation as shown below. TB gene number=number of total genes; TS gene number=number of differentially expressed host genes of circRNA in total genes; B gene number=total number of gene in all GO terms; S gene number=number of differentially expressed host genes of circRNA in this GO term. Those GO terms with p value<0.05 were defined as significant GO terms.
Significant GO terms::
| GO_ID | GO_Term | GO_function | GO_class | transcript_id | gene_id | symbol | Description | regulation | log2(fold_change) | pvalue |
| GO:0006413 | translational initiation | biological_process | 8 | ciRNA175 | ENSG00000114867 | EIF4G1 | eukaryotic translation initiation factor 4 gamma, 1 [Source:HGNC Symbol;Acc:HGNC:3296] | down | -2.96 | 0.00 |
| GO:0006413 | translational initiation | biological_process | 8 | ciRNA23 | ENSG00000110321 | EIF4G2 | eukaryotic translation initiation factor 4 gamma, 2 [Source:HGNC Symbol;Acc:HGNC:3297] | up | 1.22 | 0.00 |
| GO:0006413 | translational initiation | biological_process | 8 | ciRNA24 | ENSG00000110321 | EIF4G2 | eukaryotic translation initiation factor 4 gamma, 2 [Source:HGNC Symbol;Acc:HGNC:3297] | up | 1.22 | 0.00 |
| GO:0006413 | translational initiation | biological_process | 8 | circRNA9646 | ENSG00000104408 | EIF3E | eukaryotic translation initiation factor 3, subunit E [Source:HGNC Symbol;Acc:HGNC:3277] | up | 1.87 | 0.00 |
| GO:0006413 | translational initiation | biological_process | 8 | circRNA9647 | ENSG00000104408 | EIF3E | eukaryotic translation initiation factor 3, subunit E [Source:HGNC Symbol;Acc:HGNC:3277] | up | 1.91 | 0.00 |
| GO:0006413 | translational initiation | biological_process | 8 | circRNA9652 | ENSG00000147677 | EIF3H | eukaryotic translation initiation factor 3, subunit H [Source:HGNC Symbol;Acc:HGNC:3273] | up | 1.99 | 0.00 |
| GO:0006413 | translational initiation | biological_process | 8 | circRNA9755 | ENSG00000063046 | EIF4B | eukaryotic translation initiation factor 4B [Source:HGNC Symbol;Acc:HGNC:3285] | up | 1.32 | 0.00 |
| GO:0006413 | translational initiation | biological_process | 8 | circRNA9843 | ENSG00000107581 | EIF3A | eukaryotic translation initiation factor 3, subunit A [Source:HGNC Symbol;Acc:HGNC:3271] | up | 1.00 | 0.00 |
| GO:0006413 | translational initiation | biological_process | 8 | circRNA993 | ENSG00000107581 | EIF3A | eukaryotic translation initiation factor 3, subunit A [Source:HGNC Symbol;Acc:HGNC:3271] | up | 1.84 | 0.00 |
| GO:0010467 | gene expression | biological_process | 6 | ciRNA118 | ENSG00000197381 | ADARB1 | adenosine deaminase, RNA-specific, B1 [Source:HGNC Symbol;Acc:HGNC:226] | up | 1.86 | 0.00 |
| GO:0010467 | gene expression | biological_process | 6 | ciRNA148 | ENSG00000112855 | HARS2 | histidyl-tRNA synthetase 2, mitochondrial [Source:HGNC Symbol;Acc:HGNC:4817] | down | -1.69 | 0.00 |
| GO:0010467 | gene expression | biological_process | 6 | ciRNA151 | ENSG00000169045 | HNRNPH1 | heterogeneous nuclear ribonucleoprotein H1 (H) [Source:HGNC Symbol;Acc:HGNC:5041] | up | 1.04 | 0.00 |
| GO:0010467 | gene expression | biological_process | 6 | ciRNA175 | ENSG00000114867 | EIF4G1 | eukaryotic translation initiation factor 4 gamma, 1 [Source:HGNC Symbol;Acc:HGNC:3296] | down | -2.96 | 0.00 |
| GO:0010467 | gene expression | biological_process | 6 | ciRNA224 | ENSG00000165684 | SNAPC4 | small nuclear RNA activating complex, polypeptide 4, 190kDa [Source:HGNC Symbol;Acc:HGNC:11137] | down | -2.20 | 0.00 |
| GO:0010467 | gene expression | biological_process | 6 | ciRNA247 | ENSG00000089009 | RPL6 | ribosomal protein L6 [Source:HGNC Symbol;Acc:HGNC:10362] | up | 1.33 | 0.00 |
| GO:0010467 | gene expression | biological_process | 6 | ciRNA279 | ENSG00000140988 | RPS2 | ribosomal protein S2 [Source:HGNC Symbol;Acc:HGNC:10404] | up | 1.53 | 0.00 |
| GO:0010467 | gene expression | biological_process | 6 | ciRNA292 | ENSG00000011304 | PTBP1 | polypyrimidine tract binding protein 1 [Source:HGNC Symbol;Acc:HGNC:9583] | down | -1.25 | 0.00 |
| GO:0010467 | gene expression | biological_process | 6 | ciRNA318 | ENSG00000171453 | POLR1C | polymerase (RNA) I polypeptide C, 30kDa [Source:HGNC Symbol;Acc:HGNC:20194] | up | 4.09 | 0.00 |
| GO:0010467 | gene expression | biological_process | 6 | ciRNA358 | ENSG00000122406 | RPL5 | ribosomal protein L5 [Source:HGNC Symbol;Acc:HGNC:10360] | up | 1.37 | 0.00 |
| GO:0010467 | gene expression | biological_process | 6 | ciRNA369 | ENSG00000008988 | RPS20 | ribosomal protein S20 [Source:HGNC Symbol;Acc:HGNC:10405] | up | 1.25 | 0.00 |
| GO:0010467 | gene expression | biological_process | 6 | ciRNA372 | ENSG00000064313 | TAF2 | TAF2 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 150kDa [Source:HGNC Symbol;Acc:HGNC:11536] | up | 2.26 | 0.00 |
| GO:0010467 | gene expression | biological_process | 6 | ciRNA373 | ENSG00000178896 | EXOSC4 | exosome component 4 [Source:HGNC Symbol;Acc:HGNC:18189] | up | 2.40 | 0.00 |
| GO:0010467 | gene expression | biological_process | 6 | ciRNA391 | ENSG00000141564 | RPTOR | regulatory associated protein of MTOR, complex 1 [Source:HGNC Symbol;Acc:HGNC:30287] | up | Inf | 0.00 |
document location: summary/3_2_circRNA_differential_expression/*VS*/4_GO_Enrichment/*VS*_GO_enrichment_Gene.xlsx
Barplot of enriched GO terms:
document location: summary/3_2_circRNA_differential_expression/*VS*/4_GO_Enrichment/*VS*_GO_enrichment.png
Scatterplot of enriched GO terms:
Number of differentially expressed host genes of circRNA enriched in GO terms, p value and rich factor are shown in scatterplot. Rich factor=(number of differentially expressed host genes of circRNA in GO term)/(total number of genes in GO term). The larger rich factor is, the higher enrichment is.
document location: summary/3_2_circRNA_differential_expression/*VS*/4_GO_Enrichment/*VS*_GO_enrichment_scatterplot.pdf
KEGG (Kyoto Encyclopedia of Genes and Genomes) (http://www.kegg.jp/) is a collection of databases dealing with genomes, biological pathways, diseases, drugs, and chemical substances. KEGG is utilized for bioinformatics research and education, including data analysis in genomics, metagenomics, metabolomics and other omics studies, modeling and simulation in systems biology, and translational research in drug development.
Significant KEGG pathways were calculated by Hypergeometric equation as shown below. TB gene number=number of total genes; TS gene number=number of differentially expressed host genes of circRNA in total genes; B gene number=total number of genes in KEGG pathways; S gene number=number of differentially expressed host genes of circRNA in this KEGG pathway. Those KEGG pathways with p value<0.05 were defined as significant KEGG pathways.
Significant KEGG pathways::
| pathway_id | pathway_name | transcript_id | gene_id | symbol | Description | regulation | log2(fold_change) | pvalue |
| ko03013 | RNA transport | ciRNA175 | ENSG00000114867 | EIF4G1 | eukaryotic translation initiation factor 4 gamma, 1 [Source:HGNC Symbol;Acc:HGNC:3296] | down | -2.96 | 0.00 |
| ko03013 | RNA transport | ciRNA23 | ENSG00000110321 | EIF4G2 | eukaryotic translation initiation factor 4 gamma, 2 [Source:HGNC Symbol;Acc:HGNC:3297] | up | 1.22 | 0.00 |
| ko03013 | RNA transport | ciRNA24 | ENSG00000110321 | EIF4G2 | eukaryotic translation initiation factor 4 gamma, 2 [Source:HGNC Symbol;Acc:HGNC:3297] | up | 1.22 | 0.00 |
| ko03030 | DNA replication | circRNA8352 | ENSG00000163918 | RFC4 | replication factor C (activator 1) 4, 37kDa [Source:HGNC Symbol;Acc:HGNC:9972] | up | 3.00 | 0.01 |
| ko03030 | DNA replication | circRNA8653 | ENSG00000076003 | MCM6 | minichromosome maintenance complex component 6 [Source:HGNC Symbol;Acc:HGNC:6949] | up | 3.02 | 0.01 |
| ko03030 | DNA replication | circRNA869 | ENSG00000138346 | DNA2 | DNA replication helicase/nuclease 2 [Source:HGNC Symbol;Acc:HGNC:2939] | up | 2.53 | 0.01 |
| ko03030 | DNA replication | circRNA870 | ENSG00000138346 | DNA2 | DNA replication helicase/nuclease 2 [Source:HGNC Symbol;Acc:HGNC:2939] | up | 2.03 | 0.01 |
| ko03030 | DNA replication | circRNA871 | ENSG00000138346 | DNA2 | DNA replication helicase/nuclease 2 [Source:HGNC Symbol;Acc:HGNC:2939] | up | 2.05 | 0.01 |
| ko03030 | DNA replication | circRNA872 | ENSG00000138346 | DNA2 | DNA replication helicase/nuclease 2 [Source:HGNC Symbol;Acc:HGNC:2939] | up | 1.25 | 0.01 |
| ko03030 | DNA replication | circRNA8855 | ENSG00000117748 | RPA2 | replication protein A2, 32kDa [Source:HGNC Symbol;Acc:HGNC:10290] | up | 1.38 | 0.01 |
| ko03030 | DNA replication | circRNA9548 | ENSG00000104738 | MCM4 | minichromosome maintenance complex component 4 [Source:HGNC Symbol;Acc:HGNC:6947] | up | 3.02 | 0.01 |
| ko03030 | DNA replication | circRNA9793 | ENSG00000077514 | POLD3 | polymerase (DNA-directed), delta 3, accessory subunit [Source:HGNC Symbol;Acc:HGNC:20932] | up | 1.29 | 0.01 |
| ko03030 | DNA replication | circRNA9824 | ENSG00000138346 | DNA2 | DNA replication helicase/nuclease 2 [Source:HGNC Symbol;Acc:HGNC:2939] | up | 2.14 | 0.01 |
| ko00980 | Metabolism of xenobiotics by cytochrome P450 | ciRNA104 | ENSG00000197408 | CYP2B6 | cytochrome P450, family 2, subfamily B, polypeptide 6 [Source:HGNC Symbol;Acc:HGNC:2615] | down | -5.22 | 0.02 |
| ko00980 | Metabolism of xenobiotics by cytochrome P450 | ciRNA124 | ENSG00000106258 | CYP3A5 | cytochrome P450, family 3, subfamily A, polypeptide 5 [Source:HGNC Symbol;Acc:HGNC:2638] | down | -3.59 | 0.02 |
| ko00980 | Metabolism of xenobiotics by cytochrome P450 | ciRNA125 | ENSG00000106258 | CYP3A5 | cytochrome P450, family 3, subfamily A, polypeptide 5 [Source:HGNC Symbol;Acc:HGNC:2638] | down | -3.60 | 0.02 |
| ko00980 | Metabolism of xenobiotics by cytochrome P450 | ciRNA258 | ENSG00000198610 | AKR1C4 | aldo-keto reductase family 1, member C4 [Source:HGNC Symbol;Acc:HGNC:387] | up | 3.19 | 0.02 |
| ko00980 | Metabolism of xenobiotics by cytochrome P450 | ciRNA41 | ENSG00000151632 | AKR1C2 | aldo-keto reductase family 1, member C2 [Source:HGNC Symbol;Acc:HGNC:385] | up | 2.88 | 0.02 |
document location: summary/3_2_circRNA_differential_expression/*VS*/5_KEGG_Enrichment/*VS*_KEGG_enrichment_Gene.xlsx
Scatterplot of enriched KEGG pathways:
Number of differentially expressed host genes of circRNA enriched in KEGG pathway, p value and rich factor are shown in scatterplot. Rich factor=(number of differentially expressed host genes of circRNA in KEGG pathway)/(total number of genes in KEGG pathway). The larger rich factor is, the higher enrichment is.
document location:
summary/3_2_circRNA_differential_expression/*VS*/5_KEGG_Enrichment/*VS*_KEGG_enrichment_scatterplot.png
KEGG pathway maps:
Graphical map objects
The KEGG pathway map is a moleculalr interaction/reaction network diagram represented in terms of the KEGG Orthology (KO) groups, so that experimental evidence in specific organisms can be generalized to other organisms through genomic information. Each map is manually drawn with in-house software called KegSketch, which generates the KGML+ file. This file is an SVG file containing graphics objects that are associated with KEGG objects (see KEGG object identifiers). Basic graphics objects in the reference KEGG pathway maps are:
boxes - ortholog (KO) groups identified by K numbers and, in metabolic maps, reactions identified by R numbers as well
circles - other molecules, usually chemical compounds identified by C numbers, but including glycans identified by G numbers
lines - reactions identified by R numbers in metabolic maps; ortholog (KO) groups identified by K numbers in global metabolism maps
and in organism specific pathway maps that are computationally generated:
boxes - genes or gene products identified by the combination of the KEGG organism code and gene identifiers
These map objects can be searched in the search box at the top of the KEGG PATHWAY page, in the search box in each pathway map, and by the KEGG Mapper tools.
Convention of map number prefix
Each pathway map is identified by the combination of 2-4 letter code and 5 digit number (see KEGG Identifiers). The prefix has the following meaning:
map - Reference pathway
ko - Reference pathway (KO)
ec - Reference pathway (EC)
rn - Reference pathway (Reaction)
org - Organism-specific pathway map
Only the first reference pathway map is manually drawn; all other maps are computationally generated. For metabolic pathways, each box (or line) in the reference map is linked to the K number (KO identifeir), the EC number, and the R number (reaction identifier). The KO, EC, and reaction maps are linked to only one of them. For all metabolic and non-metabolic maps, K numbers are converted to gene identifiers in each organism to generate organism-specific pathways.
As shown above, "map" pathways are not colored, "ko/ec/rn" pathways are colored blue, and organism-specific pathways are colored green, where coloring indicates that map objects exist and are linked to corresponding entries. For global metabolism maps, "map" pathways are fully colored, so that "ko/ec/rn" pathways and organism-specific pathways are generated by reducing the coloring indicating the absence of corresponding entries.
In this study, all KEGG pathway maps were deposited in summary/3_2_circRNA_differential_expression/*VS*/5_KEGG_Enrichment/Pathway_pics/.
According to some published research articles, circRNA may function as (1) transriptional regulation in nucleus, (2) binding to RNA-binding proteins (RBPs) and RNAs besides miRNAs to form RNA-protein complexes, (3) containing an internal ribosome entry site produced a protein product, (4) regulating mRNA in the cell through limited base pairing and (5) miRNA sponge. We utilized miRanda and Targetscan to predict the interaction with circRNA and miRNA in animal and targetmimics (scripts in house) to predict the interaction with circRNA and miRNA. In animal, we could consider those high confidence results of interaction with the higher Targetscan score and lower miranda free energy.
| circRNA | chr | start | end | strand | exon Count | circType | circRNA category | isoformName | geneName | hosting gene type | flankIntron | gene Discription | GO | KEGG | miRNA | Site Type | TargetScan_score | TargetScan_score_percentile | miranda_score | miranda_Energy |
| ciRNA1 | chrX | 24207856 | 24208209 | + | 1 | ciRNA | - | ENST00000539115 | ZFX | mRNA | chrX:24207855-24208217 | zinc finger protein, X-linked [Source:HGNC Symbol;Acc:HGNC:12869] | GO:0003677(DNA binding);GO:0003713(transcription coactivator activity);GO:0005634(nucleus);GO:0006351(transcription, DNA-templated);GO:0006355(regulation of transcription, DNA-templated);GO:0046872(metal ion binding) | NA | hsa-miR-15b-3p | 8mer | -0.48 | 99 | 157 | -11.71 |
| ciRNA10 | chr12 | 7091247 | 7091451 | - | 1 | ciRNA | - | ENST00000542285 | C1R | mRNA | chr12:7090248-7091451 | complement component 1, r subcomponent [Source:HGNC Symbol;Acc:HGNC:1246] | GO:0004252(serine-type endopeptidase activity);GO:0005509(calcium ion binding);GO:0005515(protein binding);GO:0005576(extracellular region);GO:0006508(proteolysis);GO:0006955(immune response);GO:0006956(complement activation);GO:0006958(complement activation, classical pathway);GO:0008236(serine-type peptidase activity);GO:0045087(innate immune response);GO:0070062(extracellular exosome);GO:0072562(blood microparticle) | NA | hsa-miR-185-3p | 8mer | -0.24 | 83 | 164 | -25.98 |
| ciRNA100 | chr19 | 10795440 | 10796020 | + | 1 | ciRNA | - | ENST00000585892 | DNM2 | mRNA | chr19:10795439-10796060 | dynamin 2 [Source:HGNC Symbol;Acc:HGNC:2974] | GO:0000086(G2/M transition of mitotic cell cycle);GO:0000139(Golgi membrane);GO:0001891(phagocytic cup);GO:0001917(photoreceptor inner segment);GO:0002031(G-protein coupled receptor internalization);GO:0003924(GTPase activity);GO:0005515(protein binding);GO:0005525(GTP binding);GO:0005634(nucleus);GO:0005737(cytoplasm);GO:0005768(endosome);GO:0005794(Golgi apparatus);GO:0005802(trans-Golgi network);GO:0005813(centrosome);GO:0005829(cytosol);GO:0005874(microtubule);GO:0005886(plasma membrane);GO:0005905(coated pit);GO:0005925(focal adhesion);GO:0006355(regulation of transcription, DNA-templated);GO:0006892(post-Golgi vesicle-mediated transport);GO:0006893(Golgi to plasma membrane transport);GO:0006897(endocytosis);GO:0006898(receptor-mediated endocytosis);GO:0007165(signal transduction);GO:0007283(spermatogenesis);GO:0008017(microtubule binding);GO:0008152(metabolic process);GO:0009416(response to light stimulus);GO:0010592(positive regulation of lamellipodium assembly);GO:0014069(postsynaptic density);GO:0017124(SH3 domain binding);GO:0019886(antigen processing and presentation of exogenous peptide antigen via MHC class II);GO:0019899(enzyme binding);GO:0019901(protein kinase binding);GO:0030027(lamellipodium);GO:0030054(cell junction);GO:0030426(growth cone);GO:0030496(midbody);GO:0030512(negative regulation of transforming growth factor beta receptor signaling pathway);GO:0030516(regulation of axon extension);GO:0030666(endocytic vesicle membrane);GO:0031623(receptor internalization);GO:0031749(D2 dopamine receptor binding);GO:0032403(protein complex binding);GO:0032587(ruffle membrane);GO:0033572(transferrin transport);GO:0035020(regulation of Rac protein signal transduction);GO:0036312(phosphatidylinositol 3-kinase regulatory subunit binding);GO:0042220(response to cocaine);GO:0043065(positive regulation of apoptotic process);GO:0043234(protein complex);GO:0044281(small molecule metabolic process);GO:0044351(macropinocytosis);GO:0045211(postsynaptic membrane);GO:0045334(clathrin-coated endocytic vesicle);GO:0045429(positive regulation of nitric oxide biosynthetic process);GO:0045807(positive regulation of endocytosis);GO:0045893(positive regulation of transcription, DNA-templated);GO:0046209(nitric oxide metabolic process);GO:0048471(perinuclear region of cytoplasm);GO:0048489(synaptic vesicle transport);GO:0048812(neuron projection morphogenesis);GO:0050699(WW domain binding);GO:0050766(positive regulation of phagocytosis);GO:0050998(nitric-oxide synthase binding);GO:0050999(regulation of nitric-oxide synthase activity);GO:0060271(cilium morphogenesis);GO:0061024(membrane organization);GO:0070062(extracellular exosome);GO:0071245(cellular response to carbon monoxide);GO:0071481(cellular response to X-ray);GO:0071732(cellular response to nitric oxide);GO:1900026(positive regulation of substrate adhesion-dependent cell spreading);GO:1903351(cellular response to dopamine);GO:1903358(regulation of Golgi organization);GO:1903408(positive regulation of sodium:potassium-exchanging ATPase activity);GO:1903526(negative regulation of membrane tubulation) | 04144(Endocytosis);04666(Fc gamma R-mediated phagocytosis);04961(Endocrine and other factor-regulated calcium reabsorption);05100(Bacterial invasion of epithelial cells) | hsa-miR-17-3p | 8mer | -0.28 | 89 | 157 | -24.10 |
| ciRNA102 | chr19 | 16128092 | 16129553 | + | 1 | ciRNA | - | ENST00000586682 | RAB8A | mRNA | chr19:16128091-16129573 | RAB8A, member RAS oncogene family [Source:HGNC Symbol;Acc:HGNC:7007] | GO:0000086(G2/M transition of mitotic cell cycle);GO:0000139(Golgi membrane);GO:0000278(mitotic cell cycle);GO:0003924(GTPase activity);GO:0005515(protein binding);GO:0005525(GTP binding);GO:0005622(intracellular);GO:0005634(nucleus);GO:0005654(nucleoplasm);GO:0005730(nucleolus);GO:0005768(endosome);GO:0005794(Golgi apparatus);GO:0005813(centrosome);GO:0005829(cytosol);GO:0005886(plasma membrane);GO:0005929(cilium);GO:0006886(intracellular protein transport);GO:0006904(vesicle docking involved in exocytosis);GO:0006913(nucleocytoplasmic transport);GO:0006996(organelle organization);GO:0007165(signal transduction);GO:0007264(small GTPase mediated signal transduction);GO:0007409(axonogenesis);GO:0008021(synaptic vesicle);GO:0008152(metabolic process);GO:0009306(protein secretion);GO:0014069(postsynaptic density);GO:0015031(protein transport);GO:0016020(membrane);GO:0016023(cytoplasmic membrane-bounded vesicle);GO:0016079(synaptic vesicle exocytosis);GO:0017137(Rab GTPase binding);GO:0017157(regulation of exocytosis);GO:0019003(GDP binding);GO:0019901(protein kinase binding);GO:0030140(trans-Golgi network transport vesicle);GO:0030425(dendrite);GO:0030659(cytoplasmic vesicle membrane);GO:0030667(secretory granule membrane);GO:0030670(phagocytic vesicle membrane);GO:0031489(myosin V binding);GO:0031513(nonmotile primary cilium);GO:0032482(Rab protein signal transduction);GO:0032869(cellular response to insulin stimulus);GO:0032880(regulation of protein localization);GO:0036064(ciliary basal body);GO:0042384(cilium assembly);GO:0043025(neuronal cell body);GO:0045335(phagocytic vesicle);GO:0048169(regulation of long-term neuronal synaptic plasticity);GO:0048210(Golgi vesicle fusion to target membrane);GO:0051223(regulation of protein transport);GO:0055037(recycling endosome);GO:0055038(recycling endosome membrane);GO:0061024(membrane organization);GO:0070062(extracellular exosome);GO:0072372(primary cilium);GO:0072659(protein localization to plasma membrane) | NA | hsa-miR-93-3p | m8 | -0.17 | 67 | 160 | -26.86 |
| ciRNA104 | chr19 | 41004447 | 41006880 | + | 1 | ciRNA | - | ENST00000324071 | CYP2B6 | mRNA | chr19:41004446-41006904 | cytochrome P450, family 2, subfamily B, polypeptide 6 [Source:HGNC Symbol;Acc:HGNC:2615] | GO:0004497(monooxygenase activity);GO:0005506(iron ion binding);GO:0005737(cytoplasm);GO:0005789(endoplasmic reticulum membrane);GO:0006805(xenobiotic metabolic process);GO:0008202(steroid metabolic process);GO:0008392(arachidonic acid epoxygenase activity);GO:0008395(steroid hydroxylase activity);GO:0016705(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen);GO:0016712(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen);GO:0017144(drug metabolic process);GO:0019373(epoxygenase P450 pathway);GO:0019825(oxygen binding);GO:0020037(heme binding);GO:0042180(cellular ketone metabolic process);GO:0042738(exogenous drug catabolic process);GO:0043231(intracellular membrane-bounded organelle);GO:0044281(small molecule metabolic process);GO:0055114(oxidation-reduction process) | 00590(Arachidonic acid metabolism);00830(Retinol metabolism);00980(Metabolism of xenobiotics by cytochrome P450);00982(Drug metabolism - cytochrome P450);01100(Metabolic pathways) | hsa-miR-126-5p | 8mer | -0.36 | 94 | 167 | -11.47 |
| ciRNA104 | chr19 | 41004447 | 41006880 | + | 1 | ciRNA | - | ENST00000324071 | CYP2B6 | mRNA | chr19:41004446-41006904 | cytochrome P450, family 2, subfamily B, polypeptide 6 [Source:HGNC Symbol;Acc:HGNC:2615] | GO:0004497(monooxygenase activity);GO:0005506(iron ion binding);GO:0005737(cytoplasm);GO:0005789(endoplasmic reticulum membrane);GO:0006805(xenobiotic metabolic process);GO:0008202(steroid metabolic process);GO:0008392(arachidonic acid epoxygenase activity);GO:0008395(steroid hydroxylase activity);GO:0016705(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen);GO:0016712(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen);GO:0017144(drug metabolic process);GO:0019373(epoxygenase P450 pathway);GO:0019825(oxygen binding);GO:0020037(heme binding);GO:0042180(cellular ketone metabolic process);GO:0042738(exogenous drug catabolic process);GO:0043231(intracellular membrane-bounded organelle);GO:0044281(small molecule metabolic process);GO:0055114(oxidation-reduction process) | 00590(Arachidonic acid metabolism);00830(Retinol metabolism);00980(Metabolism of xenobiotics by cytochrome P450);00982(Drug metabolism - cytochrome P450);01100(Metabolic pathways) | hsa-miR-145-5p | m8 | -0.23 | 74 | 149 | -20.05 |
| ciRNA104 | chr19 | 41004447 | 41006880 | + | 1 | ciRNA | - | ENST00000324071 | CYP2B6 | mRNA | chr19:41004446-41006904 | cytochrome P450, family 2, subfamily B, polypeptide 6 [Source:HGNC Symbol;Acc:HGNC:2615] | GO:0004497(monooxygenase activity);GO:0005506(iron ion binding);GO:0005737(cytoplasm);GO:0005789(endoplasmic reticulum membrane);GO:0006805(xenobiotic metabolic process);GO:0008202(steroid metabolic process);GO:0008392(arachidonic acid epoxygenase activity);GO:0008395(steroid hydroxylase activity);GO:0016705(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen);GO:0016712(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen);GO:0017144(drug metabolic process);GO:0019373(epoxygenase P450 pathway);GO:0019825(oxygen binding);GO:0020037(heme binding);GO:0042180(cellular ketone metabolic process);GO:0042738(exogenous drug catabolic process);GO:0043231(intracellular membrane-bounded organelle);GO:0044281(small molecule metabolic process);GO:0055114(oxidation-reduction process) | 00590(Arachidonic acid metabolism);00830(Retinol metabolism);00980(Metabolism of xenobiotics by cytochrome P450);00982(Drug metabolism - cytochrome P450);01100(Metabolic pathways) | hsa-miR-185-3p | m8 | -0.12 | 53 | 145 | -22.12 |
| ciRNA104 | chr19 | 41004447 | 41006880 | + | 1 | ciRNA | - | ENST00000324071 | CYP2B6 | mRNA | chr19:41004446-41006904 | cytochrome P450, family 2, subfamily B, polypeptide 6 [Source:HGNC Symbol;Acc:HGNC:2615] | GO:0004497(monooxygenase activity);GO:0005506(iron ion binding);GO:0005737(cytoplasm);GO:0005789(endoplasmic reticulum membrane);GO:0006805(xenobiotic metabolic process);GO:0008202(steroid metabolic process);GO:0008392(arachidonic acid epoxygenase activity);GO:0008395(steroid hydroxylase activity);GO:0016705(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen);GO:0016712(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen);GO:0017144(drug metabolic process);GO:0019373(epoxygenase P450 pathway);GO:0019825(oxygen binding);GO:0020037(heme binding);GO:0042180(cellular ketone metabolic process);GO:0042738(exogenous drug catabolic process);GO:0043231(intracellular membrane-bounded organelle);GO:0044281(small molecule metabolic process);GO:0055114(oxidation-reduction process) | 00590(Arachidonic acid metabolism);00830(Retinol metabolism);00980(Metabolism of xenobiotics by cytochrome P450);00982(Drug metabolism - cytochrome P450);01100(Metabolic pathways) | hsa-miR-20a-3p | 8mer | -0.22 | 74 | 140 | -12.84 |
| ciRNA104 | chr19 | 41004447 | 41006880 | + | 1 | ciRNA | - | ENST00000324071 | CYP2B6 | mRNA | chr19:41004446-41006904 | cytochrome P450, family 2, subfamily B, polypeptide 6 [Source:HGNC Symbol;Acc:HGNC:2615] | GO:0004497(monooxygenase activity);GO:0005506(iron ion binding);GO:0005737(cytoplasm);GO:0005789(endoplasmic reticulum membrane);GO:0006805(xenobiotic metabolic process);GO:0008202(steroid metabolic process);GO:0008392(arachidonic acid epoxygenase activity);GO:0008395(steroid hydroxylase activity);GO:0016705(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen);GO:0016712(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen);GO:0017144(drug metabolic process);GO:0019373(epoxygenase P450 pathway);GO:0019825(oxygen binding);GO:0020037(heme binding);GO:0042180(cellular ketone metabolic process);GO:0042738(exogenous drug catabolic process);GO:0043231(intracellular membrane-bounded organelle);GO:0044281(small molecule metabolic process);GO:0055114(oxidation-reduction process) | 00590(Arachidonic acid metabolism);00830(Retinol metabolism);00980(Metabolism of xenobiotics by cytochrome P450);00982(Drug metabolism - cytochrome P450);01100(Metabolic pathways) | hsa-miR-20b-3p | 8mer | -0.44 | 97 | 142 | -16.44 |
| ciRNA104 | chr19 | 41004447 | 41006880 | + | 1 | ciRNA | - | ENST00000324071 | CYP2B6 | mRNA | chr19:41004446-41006904 | cytochrome P450, family 2, subfamily B, polypeptide 6 [Source:HGNC Symbol;Acc:HGNC:2615] | GO:0004497(monooxygenase activity);GO:0005506(iron ion binding);GO:0005737(cytoplasm);GO:0005789(endoplasmic reticulum membrane);GO:0006805(xenobiotic metabolic process);GO:0008202(steroid metabolic process);GO:0008392(arachidonic acid epoxygenase activity);GO:0008395(steroid hydroxylase activity);GO:0016705(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen);GO:0016712(oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen);GO:0017144(drug metabolic process);GO:0019373(epoxygenase P450 pathway);GO:0019825(oxygen binding);GO:0020037(heme binding);GO:0042180(cellular ketone metabolic process);GO:0042738(exogenous drug catabolic process);GO:0043231(intracellular membrane-bounded organelle);GO:0044281(small molecule metabolic process);GO:0055114(oxidation-reduction process) | 00590(Arachidonic acid metabolism);00830(Retinol metabolism);00980(Metabolism of xenobiotics by cytochrome P450);00982(Drug metabolism - cytochrome P450);01100(Metabolic pathways) | hsa-miR-221-5p | m8 | -0.22 | 79 | 164 | -21.83 |
| ciRNA105 | chr19 | 45821522 | 45822755 | - | 1 | ciRNA | - | ENST00000598155 | SYMPK | mRNA | chr19:45821485-45822755 | symplekin [Source:HGNC Symbol;Acc:HGNC:22935] | GO:0005488(binding);GO:0005515(protein binding);GO:0005654(nucleoplasm);GO:0005737(cytoplasm);GO:0005856(cytoskeleton);GO:0005886(plasma membrane);GO:0005923(bicellular tight junction);GO:0006378(mRNA polyadenylation);GO:0007155(cell adhesion);GO:0035307(positive regulation of protein dephosphorylation) | 03015(mRNA surveillance pathway);04530(Tight junction) | hsa-miR-125b-5p | 8mer | -0.18 | 67 | 140 | -19.34 |
| ciRNA105 | chr19 | 45821522 | 45822755 | - | 1 | ciRNA | - | ENST00000598155 | SYMPK | mRNA | chr19:45821485-45822755 | symplekin [Source:HGNC Symbol;Acc:HGNC:22935] | GO:0005488(binding);GO:0005515(protein binding);GO:0005654(nucleoplasm);GO:0005737(cytoplasm);GO:0005856(cytoskeleton);GO:0005886(plasma membrane);GO:0005923(bicellular tight junction);GO:0006378(mRNA polyadenylation);GO:0007155(cell adhesion);GO:0035307(positive regulation of protein dephosphorylation) | 03015(mRNA surveillance pathway);04530(Tight junction) | hsa-miR-29a-3p | 8mer | -0.28 | 88 | 144 | -17.36 |
| ciRNA105 | chr19 | 45821522 | 45822755 | - | 1 | ciRNA | - | ENST00000598155 | SYMPK | mRNA | chr19:45821485-45822755 | symplekin [Source:HGNC Symbol;Acc:HGNC:22935] | GO:0005488(binding);GO:0005515(protein binding);GO:0005654(nucleoplasm);GO:0005737(cytoplasm);GO:0005856(cytoskeleton);GO:0005886(plasma membrane);GO:0005923(bicellular tight junction);GO:0006378(mRNA polyadenylation);GO:0007155(cell adhesion);GO:0035307(positive regulation of protein dephosphorylation) | 03015(mRNA surveillance pathway);04530(Tight junction) | hsa-miR-29c-3p | 8mer | -0.28 | 87 | 140 | -15.50 |
| ciRNA105 | chr19 | 45821522 | 45822755 | - | 1 | ciRNA | - | ENST00000598155 | SYMPK | mRNA | chr19:45821485-45822755 | symplekin [Source:HGNC Symbol;Acc:HGNC:22935] | GO:0005488(binding);GO:0005515(protein binding);GO:0005654(nucleoplasm);GO:0005737(cytoplasm);GO:0005856(cytoskeleton);GO:0005886(plasma membrane);GO:0005923(bicellular tight junction);GO:0006378(mRNA polyadenylation);GO:0007155(cell adhesion);GO:0035307(positive regulation of protein dephosphorylation) | 03015(mRNA surveillance pathway);04530(Tight junction) | hsa-miR-92a-2-5p | 8mer | -0.21 | 83 | 167 | -32.33 |
| ciRNA108 | chr19 | 58498355 | 58498493 | - | 1 | ciRNA | - | ENST00000595851 | SLC27A5 | mRNA | chr19:58483646-58498493 | solute carrier family 27 (fatty acid transporter), member 5 [Source:HGNC Symbol;Acc:HGNC:10999] | GO:0000038(very long-chain fatty acid metabolic process);GO:0001676(long-chain fatty acid metabolic process);GO:0003824(catalytic activity);GO:0004467(long-chain fatty acid-CoA ligase activity);GO:0005524(ATP binding);GO:0005783(endoplasmic reticulum);GO:0005789(endoplasmic reticulum membrane);GO:0006642(triglyceride mobilization);GO:0006699(bile acid biosynthetic process);GO:0008152(metabolic process);GO:0008206(bile acid metabolic process);GO:0009925(basal plasma membrane);GO:0015245(fatty acid transporter activity);GO:0015721(bile acid and bile salt transport);GO:0015908(fatty acid transport);GO:0015911(plasma membrane long-chain fatty acid transport);GO:0016021(integral component of membrane);GO:0030176(integral component of endoplasmic reticulum membrane);GO:0031957(very long-chain fatty acid-CoA ligase activity);GO:0032403(protein complex binding);GO:0043231(intracellular membrane-bounded organelle);GO:0043234(protein complex);GO:0044281(small molecule metabolic process);GO:0046951(ketone body biosynthetic process);GO:0047747(cholate-CoA ligase activity) | 00120(Primary bile acid biosynthesis);01100(Metabolic pathways);03320(PPAR signaling pathway);04976(Bile secretion) | hsa-miR-92a-2-5p | m8 | -0.20 | 82 | 152 | -22.19 |
| ciRNA11 | chr12 | 9164990 | 9165138 | - | 1 | ciRNA | - | ENST00000261336 | PZP | mRNA | chr12:9164259-9165138 | pregnancy-zone protein [Source:HGNC Symbol;Acc:HGNC:9750] | GO:0004866(endopeptidase inhibitor activity);GO:0004867(serine-type endopeptidase inhibitor activity);GO:0005576(extracellular region);GO:0005615(extracellular space);GO:0007565(female pregnancy);GO:0010951(negative regulation of endopeptidase activity);GO:0070062(extracellular exosome);GO:0072562(blood microparticle) | NA | hsa-miR-222-5p | m8 | -0.20 | 74 | 148 | -14.25 |
| ciRNA112 | chr20 | 44424255 | 44428334 | + | 1 | ciRNA | - | ENST00000316673 | HNF4A | mRNA | chr20:44424254-44428334 | hepatocyte nuclear factor 4, alpha [Source:HGNC Symbol;Acc:HGNC:5024] | GO:0000979(RNA polymerase II core promoter sequence-specific DNA binding);GO:0001077(RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription);GO:0001102(RNA polymerase II activating transcription factor binding);GO:0001228(RNA polymerase II transcription regulatory region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription);GO:0003677(DNA binding);GO:0003700(sequence-specific DNA binding transcription factor activity);GO:0003705(RNA polymerase II distal enhancer sequence-specific DNA binding transcription factor activity);GO:0003707(steroid hormone receptor activity);GO:0004879(ligand-activated sequence-specific DNA binding RNA polymerase II transcription factor activity);GO:0005102(receptor binding);GO:0005504(fatty acid binding);GO:0005515(protein binding);GO:0005634(nucleus);GO:0005654(nucleoplasm);GO:0005737(cytoplasm);GO:0006351(transcription, DNA-templated);GO:0006355(regulation of transcription, DNA-templated);GO:0006357(regulation of transcription from RNA polymerase II promoter);GO:0006366(transcription from RNA polymerase II promoter);GO:0006367(transcription initiation from RNA polymerase II promoter);GO:0006591(ornithine metabolic process);GO:0006629(lipid metabolic process);GO:0006805(xenobiotic metabolic process);GO:0007548(sex differentiation);GO:0007596(blood coagulation);GO:0008270(zinc ion binding);GO:0008285(negative regulation of cell proliferation);GO:0009749(response to glucose);GO:0010467(gene expression);GO:0010470(regulation of gastrulation);GO:0019216(regulation of lipid metabolic process);GO:0023019(signal transduction involved in regulation of gene expression);GO:0030308(negative regulation of cell growth);GO:0030522(intracellular receptor signaling pathway);GO:0031018(endocrine pancreas development);GO:0042593(glucose homeostasis);GO:0042803(protein homodimerization activity);GO:0043401(steroid hormone mediated signaling pathway);GO:0043565(sequence-specific DNA binding);GO:0044212(transcription regulatory region DNA binding);GO:0045893(positive regulation of transcription, DNA-templated);GO:0045944(positive regulation of transcription from RNA polymerase II promoter);GO:0050796(regulation of insulin secretion);GO:0055088(lipid homeostasis);GO:0055091(phospholipid homeostasis);GO:0060395(SMAD protein signal transduction);GO:0060398(regulation of growth hormone receptor signaling pathway);GO:0070328(triglyceride homeostasis);GO:2000189(positive regulation of cholesterol homeostasis) | 04950(Maturity onset diabetes of the young) | hsa-miR-106a-3p | 8mer | -0.36 | 93 | 154 | -12.35 |
| ciRNA112 | chr20 | 44424255 | 44428334 | + | 1 | ciRNA | - | ENST00000316673 | HNF4A | mRNA | chr20:44424254-44428334 | hepatocyte nuclear factor 4, alpha [Source:HGNC Symbol;Acc:HGNC:5024] | GO:0000979(RNA polymerase II core promoter sequence-specific DNA binding);GO:0001077(RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription);GO:0001102(RNA polymerase II activating transcription factor binding);GO:0001228(RNA polymerase II transcription regulatory region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription);GO:0003677(DNA binding);GO:0003700(sequence-specific DNA binding transcription factor activity);GO:0003705(RNA polymerase II distal enhancer sequence-specific DNA binding transcription factor activity);GO:0003707(steroid hormone receptor activity);GO:0004879(ligand-activated sequence-specific DNA binding RNA polymerase II transcription factor activity);GO:0005102(receptor binding);GO:0005504(fatty acid binding);GO:0005515(protein binding);GO:0005634(nucleus);GO:0005654(nucleoplasm);GO:0005737(cytoplasm);GO:0006351(transcription, DNA-templated);GO:0006355(regulation of transcription, DNA-templated);GO:0006357(regulation of transcription from RNA polymerase II promoter);GO:0006366(transcription from RNA polymerase II promoter);GO:0006367(transcription initiation from RNA polymerase II promoter);GO:0006591(ornithine metabolic process);GO:0006629(lipid metabolic process);GO:0006805(xenobiotic metabolic process);GO:0007548(sex differentiation);GO:0007596(blood coagulation);GO:0008270(zinc ion binding);GO:0008285(negative regulation of cell proliferation);GO:0009749(response to glucose);GO:0010467(gene expression);GO:0010470(regulation of gastrulation);GO:0019216(regulation of lipid metabolic process);GO:0023019(signal transduction involved in regulation of gene expression);GO:0030308(negative regulation of cell growth);GO:0030522(intracellular receptor signaling pathway);GO:0031018(endocrine pancreas development);GO:0042593(glucose homeostasis);GO:0042803(protein homodimerization activity);GO:0043401(steroid hormone mediated signaling pathway);GO:0043565(sequence-specific DNA binding);GO:0044212(transcription regulatory region DNA binding);GO:0045893(positive regulation of transcription, DNA-templated);GO:0045944(positive regulation of transcription from RNA polymerase II promoter);GO:0050796(regulation of insulin secretion);GO:0055088(lipid homeostasis);GO:0055091(phospholipid homeostasis);GO:0060395(SMAD protein signal transduction);GO:0060398(regulation of growth hormone receptor signaling pathway);GO:0070328(triglyceride homeostasis);GO:2000189(positive regulation of cholesterol homeostasis) | 04950(Maturity onset diabetes of the young) | hsa-miR-145-3p | m8 | -0.23 | 72 | 142 | -16.30 |
| ciRNA112 | chr20 | 44424255 | 44428334 | + | 1 | ciRNA | - | ENST00000316673 | HNF4A | mRNA | chr20:44424254-44428334 | hepatocyte nuclear factor 4, alpha [Source:HGNC Symbol;Acc:HGNC:5024] | GO:0000979(RNA polymerase II core promoter sequence-specific DNA binding);GO:0001077(RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription);GO:0001102(RNA polymerase II activating transcription factor binding);GO:0001228(RNA polymerase II transcription regulatory region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription);GO:0003677(DNA binding);GO:0003700(sequence-specific DNA binding transcription factor activity);GO:0003705(RNA polymerase II distal enhancer sequence-specific DNA binding transcription factor activity);GO:0003707(steroid hormone receptor activity);GO:0004879(ligand-activated sequence-specific DNA binding RNA polymerase II transcription factor activity);GO:0005102(receptor binding);GO:0005504(fatty acid binding);GO:0005515(protein binding);GO:0005634(nucleus);GO:0005654(nucleoplasm);GO:0005737(cytoplasm);GO:0006351(transcription, DNA-templated);GO:0006355(regulation of transcription, DNA-templated);GO:0006357(regulation of transcription from RNA polymerase II promoter);GO:0006366(transcription from RNA polymerase II promoter);GO:0006367(transcription initiation from RNA polymerase II promoter);GO:0006591(ornithine metabolic process);GO:0006629(lipid metabolic process);GO:0006805(xenobiotic metabolic process);GO:0007548(sex differentiation);GO:0007596(blood coagulation);GO:0008270(zinc ion binding);GO:0008285(negative regulation of cell proliferation);GO:0009749(response to glucose);GO:0010467(gene expression);GO:0010470(regulation of gastrulation);GO:0019216(regulation of lipid metabolic process);GO:0023019(signal transduction involved in regulation of gene expression);GO:0030308(negative regulation of cell growth);GO:0030522(intracellular receptor signaling pathway);GO:0031018(endocrine pancreas development);GO:0042593(glucose homeostasis);GO:0042803(protein homodimerization activity);GO:0043401(steroid hormone mediated signaling pathway);GO:0043565(sequence-specific DNA binding);GO:0044212(transcription regulatory region DNA binding);GO:0045893(positive regulation of transcription, DNA-templated);GO:0045944(positive regulation of transcription from RNA polymerase II promoter);GO:0050796(regulation of insulin secretion);GO:0055088(lipid homeostasis);GO:0055091(phospholipid homeostasis);GO:0060395(SMAD protein signal transduction);GO:0060398(regulation of growth hormone receptor signaling pathway);GO:0070328(triglyceride homeostasis);GO:2000189(positive regulation of cholesterol homeostasis) | 04950(Maturity onset diabetes of the young) | hsa-miR-182-5p | 8mer | -0.18 | 67 | 148 | -16.97 |
| ciRNA113 | chr20 | 57563216 | 57563428 | + | 1 | ciRNA | - | ENST00000319441 | PCK1 | mRNA | chr20:57563215-57563564 | phosphoenolpyruvate carboxykinase 1 (soluble) [Source:HGNC Symbol;Acc:HGNC:8724] | GO:0000287(magnesium ion binding);GO:0004611(phosphoenolpyruvate carboxykinase activity);GO:0004613(phosphoenolpyruvate carboxykinase (GTP) activity);GO:0005525(GTP binding);GO:0005737(cytoplasm);GO:0005829(cytosol);GO:0005975(carbohydrate metabolic process);GO:0006006(glucose metabolic process);GO:0006094(gluconeogenesis);GO:0006107(oxaloacetate metabolic process);GO:0006475(internal protein amino acid acetylation);GO:0006629(lipid metabolic process);GO:0014823(response to activity);GO:0017076(purine nucleotide binding);GO:0017144(drug metabolic process);GO:0019003(GDP binding);GO:0030145(manganese ion binding);GO:0031406(carboxylic acid binding);GO:0032868(response to insulin);GO:0042593(glucose homeostasis);GO:0044281(small molecule metabolic process);GO:0046327(glycerol biosynthetic process from pyruvate);GO:0051365(cellular response to potassium ion starvation);GO:0061402(positive regulation of transcription from RNA polymerase II promoter in response to acidic pH);GO:0070062(extracellular exosome) | 00010(Glycolysis / Gluconeogenesis);00020(Citrate cycle (TCA cycle));00620(Pyruvate metabolism);01100(Metabolic pathways);03320(PPAR signaling pathway);04910(Insulin signaling pathway);04920(Adipocytokine signaling pathway);04964(Proximal tubule bicarbonate reclamation) | hsa-miR-92a-2-5p | 8mer | -0.43 | 98 | 152 | -25.61 |
| ciRNA114 | chr20 | 62812556 | 62812902 | + | 1 | ciRNA | - | ENST00000621591 | OGFR | mRNA | chr20:62812555-62813497 | opioid growth factor receptor [Source:HGNC Symbol;Acc:HGNC:15768] | GO:0001558(regulation of cell growth);GO:0004872(receptor activity);GO:0004985(opioid receptor activity);GO:0005575(cellular_component);GO:0005634(nucleus);GO:0005737(cytoplasm);GO:0016020(membrane);GO:0038003(opioid receptor signaling pathway) | NA | hsa-miR-185-3p | 1a | -0.12 | 51 | 140 | -20.12 |
| ciRNA114 | chr20 | 62812556 | 62812902 | + | 1 | ciRNA | - | ENST00000621591 | OGFR | mRNA | chr20:62812555-62813497 | opioid growth factor receptor [Source:HGNC Symbol;Acc:HGNC:15768] | GO:0001558(regulation of cell growth);GO:0004872(receptor activity);GO:0004985(opioid receptor activity);GO:0005575(cellular_component);GO:0005634(nucleus);GO:0005737(cytoplasm);GO:0016020(membrane);GO:0038003(opioid receptor signaling pathway) | NA | hsa-miR-31-3p | 8mer | -0.27 | 84 | 140 | -13.66 |
| ciRNA116 | chr21 | 26943185 | 26943379 | - | 1 | ciRNA | - | ENST00000284987 | ADAMTS5 | mRNA | chr21:26934749-26943379 | ADAM metallopeptidase with thrombospondin type 1 motif, 5 [Source:HGNC Symbol;Acc:HGNC:221] | GO:0004222(metalloendopeptidase activity);GO:0005178(integrin binding);GO:0005515(protein binding);GO:0005576(extracellular region);GO:0005578(proteinaceous extracellular matrix);GO:0005788(endoplasmic reticulum lumen);GO:0006493(protein O-linked glycosylation);GO:0006508(proteolysis);GO:0008237(metallopeptidase activity);GO:0008270(zinc ion binding);GO:0022617(extracellular matrix disassembly);GO:0030198(extracellular matrix organization);GO:0031012(extracellular matrix);GO:0036066(protein O-linked fucosylation);GO:0042742(defense response to bacterium);GO:0043687(post-translational protein modification);GO:0044267(cellular protein metabolic process) | NA | hsa-miR-31-5p | m8 | -0.24 | 78 | 150 | -15.29 |
| ciRNA117 | chr21 | 34509408 | 34511100 | - | 1 | ciRNA | - | ENST00000611936 | KCNE1 | mRNA | chr21:34449684-34511100 | potassium channel, voltage gated subfamily E regulatory beta subunit 1 [Source:HGNC Symbol;Acc:HGNC:6240] | GO:0005249(voltage-gated potassium channel activity);GO:0005251(delayed rectifier potassium channel activity);GO:0005515(protein binding);GO:0005764(lysosome);GO:0005886(plasma membrane);GO:0006487(protein N-linked glycosylation);GO:0006493(protein O-linked glycosylation);GO:0006811(ion transport);GO:0007605(sensory perception of sound);GO:0008076(voltage-gated potassium channel complex);GO:0009986(cell surface);GO:0015459(potassium channel regulator activity);GO:0016020(membrane);GO:0016324(apical plasma membrane);GO:0030018(Z disc);GO:0031433(telethonin binding);GO:0060307(regulation of ventricular cardiac muscle cell membrane repolarization);GO:0071320(cellular response to cAMP);GO:0071435(potassium ion export);GO:0071805(potassium ion transmembrane transport);GO:0086002(cardiac muscle cell action potential involved in contraction);GO:0086005(ventricular cardiac muscle cell action potential);GO:0086008(voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization);GO:0086009(membrane repolarization);GO:0086011(membrane repolarization during action potential);GO:0086013(membrane repolarization during cardiac muscle cell action potential);GO:0086091(regulation of heart rate by cardiac conduction);GO:0090315(negative regulation of protein targeting to membrane);GO:1901379(regulation of potassium ion transmembrane transport);GO:1901381(positive regulation of potassium ion transmembrane transport);GO:1902259(regulation of delayed rectifier potassium channel activity);GO:1902260(negative regulation of delayed rectifier potassium channel activity);GO:1902282(voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization) | NA | hsa-miR-199a-3p | m8 | -0.20 | 71 | 143 | -14.87 |
| ciRNA117 | chr21 | 34509408 | 34511100 | - | 1 | ciRNA | - | ENST00000611936 | KCNE1 | mRNA | chr21:34449684-34511100 | potassium channel, voltage gated subfamily E regulatory beta subunit 1 [Source:HGNC Symbol;Acc:HGNC:6240] | GO:0005249(voltage-gated potassium channel activity);GO:0005251(delayed rectifier potassium channel activity);GO:0005515(protein binding);GO:0005764(lysosome);GO:0005886(plasma membrane);GO:0006487(protein N-linked glycosylation);GO:0006493(protein O-linked glycosylation);GO:0006811(ion transport);GO:0007605(sensory perception of sound);GO:0008076(voltage-gated potassium channel complex);GO:0009986(cell surface);GO:0015459(potassium channel regulator activity);GO:0016020(membrane);GO:0016324(apical plasma membrane);GO:0030018(Z disc);GO:0031433(telethonin binding);GO:0060307(regulation of ventricular cardiac muscle cell membrane repolarization);GO:0071320(cellular response to cAMP);GO:0071435(potassium ion export);GO:0071805(potassium ion transmembrane transport);GO:0086002(cardiac muscle cell action potential involved in contraction);GO:0086005(ventricular cardiac muscle cell action potential);GO:0086008(voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization);GO:0086009(membrane repolarization);GO:0086011(membrane repolarization during action potential);GO:0086013(membrane repolarization during cardiac muscle cell action potential);GO:0086091(regulation of heart rate by cardiac conduction);GO:0090315(negative regulation of protein targeting to membrane);GO:1901379(regulation of potassium ion transmembrane transport);GO:1901381(positive regulation of potassium ion transmembrane transport);GO:1902259(regulation of delayed rectifier potassium channel activity);GO:1902260(negative regulation of delayed rectifier potassium channel activity);GO:1902282(voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization) | NA | hsa-miR-221-5p | m8 | -0.13 | 56 | 149 | -19.56 |
document location: summary/3_3_circRNA_miRNA_network/1_predicted_miRNAs_bind_to_circRNAs.xlsx
2575 West Bellfort Street
Suite 270
Houston, TX
77054 USA
Local (713) 664-7087
Toll Free: 1-888-528-8818
Fax: (713) 664-8181